SUBSTITUTED INDOLINE DERIVATIVES AS DENGUE VIRAL REPLICATION INHIBITORS

Abstract

The present invention concerns substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.

##STR00001##

Claims

1-14. (canceled)

15. A method of inhibiting dengue virus replication comprising contacting the dengue virus with a compound selected from the group consisting of: ##STR00060## ##STR00061## ##STR00062## and stereoisomeric forms, pharmaceutically acceptable salts, solvates or polymorphs thereof.

16. A compound having the formula 4: ##STR00063## wherein said compound is: Enantiomer 4A, wherein .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.7 Hz, 2H) 2.34 (br t, J=7.3 Hz, 2H) 3.08-3.27 (m, 2H) 3.62 (s, 3H) 3.85 (br t, J=6.3 Hz, 2H) 3.99-4.11 (m, 1H) 4.47-4.57 (m, 1H) 5.57 (br s, 1H) 5.76 (s, 1H) 5.95 (br d, J=10.1 Hz, 2H) 6.45 (br s, 1H) 7.01 (br d, J=7.6 Hz, 1H) 7.34 (br d, J=7.9 Hz, 1H) 7.44 (br d, J=8.5 Hz, 2H) 7.55 (br d, J=8.2 Hz, 2H) 8.04 (br s, 1H) 12.12 (br s, 1H); LC/MS (method LC-A): R.sub.t 2.95 min, MH.sup.+ 579; [].sub.D.sup.20: 48.5 (c 0.27, DMF); Chiral SFC (method SFC-A): R.sub.t 1.13 min, MH.sup.+ 579, chiral purity 100%; or or a pharmaceutically acceptable salt or solvate thereof.

17. A compound having the formula 4: ##STR00064## wherein said compound is: Enantiomer 4B, wherein, .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (br t, J=6.8 Hz, 2H) 2.34 (br t, J=7.3 Hz, 2H) 3.09-3.27 (m, 2H) 3.62 (s, 3H) 3.85 (br t, J=6.1 Hz, 2H) 3.99-4.10 (m, 1H) 4.46-4.59 (m, 1H) 5.57 (s, 1H) 5.76 (br s, 1H) 5.95 (br d, J=10.1 Hz, 2H) 6.45 (br s, 1H) 7.01 (br d, J=7.9 Hz, 1H) 7.34 (br d, J=7.9 Hz, 1H) 7.44 (br d, J=8.2 Hz, 2H) 7.55 (br d, J=8.2 Hz, 2H) 8.04 (br s, 1H) 12.12 (br s, 1H); LC/MS (method LC-A): R.sub.t 2.94 min, MH.sup.+579; [].sub.D.sup.20: +42.9 (c 0.28, DMF); Chiral SFC (method SFC-A): R.sub.t 2.13 min, MH.sup.+579, chiral purity 100%; or a pharmaceutically acceptable salt or solvate thereof.

Description

EXAMPLES

LC/MS Methods

[0035] The High Performance Liquid Chromatography (HPLC) measurement was performed using a LC pump, a diode-array (DAD) or a UV detector and a column as specified in the respective methods. If necessary, additional detectors were included (see table of methods below).

[0036] Flow from the column was brought to the Mass Spectrometer (MS) which was configured with an atmospheric pressure ion source. It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time . . . ) in order to obtain ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software.

[0037] Compounds are described by their experimental retention times (R.sub.t) and ions. If not specified differently in the table of data, the reported molecular ion corresponds to the [M+H].sup.+ (protonated molecule) and/or [MH].sup. (deprotonated molecule). In case the compound was not directly ionizable the type of adduct is specified (i.e. [M+NH.sub.4].sup.+, [M+HCOO].sup., etc. . . . ). For molecules with multiple isotopic patterns (Br, Cl), the reported value is the one obtained for the lowest isotope mass. All results were obtained with experimental uncertainties that are commonly associated with the method used.

[0038] Hereinafter, SQD means Single Quadrupole Detector, MSD Mass Selective Detector, RT room temperature, BEH bridged ethylsiloxane/silica hybrid, DAD Diode Array Detector, HSS High Strength silica.

[0039] LC/MS Method codes (Flow expressed in mL/min; column temperature (T) in C.; Run time in minutes)

TABLE-US-00001 Run Method Flow time code Instrument Column Mobile phase Gradient Col T (min) LC-A Waters: Waters: BEH A: 95% 84.2% A for 0.49 min, 0.343 mL/min 6.2 Acquity C18 (1.7 m, CH.sub.3COONH.sub.4 to 10.5% A in 2.18 min, 40 C. UPLC - 2.1 100 mm) 7 mM/5% held for 1.94 min, back DAD-Quattro CH.sub.3CN, B: to 84.2% A in 0.73 min, Micro CH.sub.3CN held for 0.73 min. LC-B Waters: Waters A: CH.sub.3COONH.sub.4 84.2% A/15.8% B to 0.343 mL/min 6.1 Acquity BEH 7 mM 95%/ 10.5% A in 2.18 min, 40 C. H-Class - C18 (1.7 m, CH.sub.3CN 5%, B: held for 1.96 min, back DAD and 2.1 100 mm) CH.sub.3CN to 84.2% A/15.8% B in SQD2TM 0.73 min, held for 0.49 min. LC-C Waters: Waters: HSS A: 0.1% 50% A to 10% A in 3.5 0.5 mL/min 5 Acquity C18 (1.8 m, HCOOH min, held for 1.5 min. 40 C. UPLC - 2.1 50 mm) B: CH.sub.3CN DAD- Acquity TQ detector LC-D Waters: Waters: BEH A: 10 mM from 95% A to 5% A in 0.8 mL/min 2 Acquity C18 (1.7 m, CH.sub.3COONH.sub.4 in 1.3 min, held for 0.7 55 C. UPLC - 2.1 50 mm) 95% H.sub.2O + 5% min. DAD-SQD CH.sub.3CN B: CH.sub.3CN

SFC/MS Methods

[0040] The SFC measurement was performed using an Analytical Supercritical fluid chromatography (SFC) system composed by a binary pump for delivering carbon dioxide (CO.sub.2) and modifier, an autosampler, a column oven, a diode array detector equipped with a high-pressure flow cell standing up to 400 bars. If configured with a Mass Spectrometer (MS) the flow from the column was brought to the (MS). It is within the knowledge of the skilled person to set the tune parameters (e.g. scanning range, dwell time . . . ) in order to obtain ions allowing the identification of the compound's nominal monoisotopic molecular weight (MW). Data acquisition was performed with appropriate software.

[0041] Analytical SFC/MS Methods (Flow expressed in mL/min; column temperature (T) in C.; Run time in minutes, Backpressure (BPR) in bars.

TABLE-US-00002 Flow Run time Method code column mobile phase gradient Col T BPR SFC-A Daicel Chiralcel OD- A: CO.sub.2 40% B hold 3 min 3.5 3 3 column (3 m, 100 B: iPrOH 35 105 4.6 mm) (+0.3% iPrNH.sub.2) SFC-B Daicel Chiralcel OD- A: CO.sub.2 40% B hold 7 min 3 7 H column (5 m, 150 B: MeOH 35 100 4.6 mm) SFC-C Daicel Chiralcel OD- A: CO.sub.2 40% B hold 7 min 3 7 H column (5 m, 150 B: iPrOH 35 100 4.6 mm) SFC-D Daicel Chiralpak AD- A: CO.sub.2 50% B hold 7 min 3 7 H column (5 m, 150 B: iPrOH 35 100 4.6 mm) (+0.3% iPrNH.sub.2) SFC-E Daicel Chiralcel OD- A: CO.sub.2 30% B hold 7 min 3 7 H column (5 m, 150 B: EtOH 35 100 4.6 mm) SFC-F Daicel Chiralcel OD- A: CO.sub.2 30% B hold 7 min 3 7 H column (5 m, 150 B: iPrOH 35 100 4.6 mm) SFC-G Daicel Chiralcel OD- A: CO.sub.2 30% B hold 7 min 3 7 H column (3 m, 150 B: iPrOH 35 100 4.6 mm) (+0.3% iPrNH.sub.2) SFC-H Daicel Chiralpak IC A: CO.sub.2 30% B hold 7 min 3 7 column (5 m, 150 B: iPrOH 35 100 4.6 mm) (+0.3% iPrNH.sub.2) SFC-I Daicel Chiralpak AD- A: CO.sub.2 50% B hold 3 min 3.5 3 3 column (3 m, 100 B: iPrOH 35 103 4.6 mm) (+0.3% iPrNH.sub.2) SFC-J Daicel Chiralpak AS3 A: CO.sub.2 10%-50% B in 6 2.5 9.5 column (3.0 m, 150 B: EtOH min, hold 3.5 min 40 110 4.6 mm) (+0.2% iPrNH.sub.2 + 3% H.sub.2O)

Melting Points

[0042] Values are either peak values or melt ranges, and are obtained with experimental uncertainties that are commonly associated with this analytical method.

DSC823e (Indicated as DSC)

[0043] For a number of compounds, melting points were determined with a DSC823e (Mettler-Toledo). Melting points were measured with a temperature gradient of 10 C./minute. Maximum temperature was 300 C.

Optical Rotations:

[0044] Optical rotations were measured on a Perkin-Elmer 341 polarimeter with a sodium lamp and reported as follows: [] (, c g/100 ml, solvent, T C.). [].sub..sup.T=(100)/(lc): where l is the path length in dm and c is the concentration in g/100 ml for a sample at a temperature T CC) and a wavelength (in nm). If the wavelength of light used is 589 nm (the sodium D line), then the symbol D might be used instead. The sign of the rotation (+ or ) should always be given. When using this equation the concentration and solvent are always provided in parentheses after the rotation. The rotation is reported using degrees and no units of concentration are given (it is assumed to be g/100 ml).

Example 1: Synthesis of 4-(3-((1-(4-fluorophenyl)-2-oxo-2-(6-(trifluoromethyl)-indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic Acid (Compound 1) and Chiral Separation into Enantiomers 1A and 1B

[0045] ##STR00008## ##STR00009##

Synthesis of Intermediate 1a

[0046] To a mechanically stirred solution of tert-butyl 4-bromobutanoate [CAS 110661-91-1] (42.3 g, 0.19 mol) in DMF (600 mL) was added in portions a solid mixture of 3-amino-5-methoxyphenol [CAS 162155-27-3] (26.4 g, 0.19 mol) and Cs.sub.2CO.sub.3 (123.6 g, 0.379 mol). The reaction was stirred at 60 C. for 65 h, and allowed to reach room temperature. The mixture was poured out into H.sub.2O (2.5 L). The product was extracted with Et.sub.2O (2 times). The combined organic layers were washed with brine, dried over MgSO.sub.4 and filtered off. The solvent was evaporated under reduced pressure, and then co-evaporated with toluene. The residue was purified via Normal Phase HPLC (Stationary phase: silica gel 60A 25-40 m (Merck), Mobile phase: gradient from 20% EtOAc, 80% heptane to 60% EtOAc, 40% heptane) yielding tert-butyl 4-(3-amino-5-methoxyphenoxy)butanoate 1a (27 g).

Synthesis of Intermediate 1b

[0047] A mixture of methyl 2-bromo-2-(4-fluorophenyl)acetate [CAS 71783-54-5] (0.400 g, 1.62 mmol), tert-butyl 4-(3-amino-5-methoxyphenoxy)butanoate 1a (0.547 g, 1.94 mmol) and triethylamine (0.337 mL, 2.43 mmol) in CH.sub.3CN (4 mL) was heated in a microwave oven at 100 C. for 20 min. The reaction mixture was diluted with EtOAc and washed with 1N HCl. The organic phase was washed with H.sub.2O and brine, dried over MgSO.sub.4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using a gradient of EtOAc (2% to 20%) in heptane to give tert-butyl 4-(3-((1-(4-fluorophenyl)-2-methoxy-2-oxoethyl)amino)-5-methoxyphenoxy)butanoate 1b (0.511 g).

Synthesis of Intermediate 1c

[0048] To a solution of tert-butyl 4-(3-((1-(4-fluorophenyl)-2-methoxy-2-oxoethyl)amino)-5-methoxyphenoxy)butanoate 1b (0.510 g, 1.14 mmol) in a solvent mixture of THF (3 mL), MeOH (3 mL) and H.sub.2O (3 mL) was added lithium hydroxide (0.239 g, 5.70 mmol). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was partially concentrated under reduced pressure to remove the organic solvents. The residue was acidified with 1N HCl and extracted with CH.sub.2Cl.sub.2. The organic phase was dried over MgSO.sub.4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using a gradient of MeOH (0% to 10%) in CH.sub.2Cl.sub.2 (containing 2% of acetic acid) to give 2-((3-(4-(tert-butoxy)-4-oxobutoxy)-5-methoxyphenyl)amino)-2-(4-fluoro-phenyl)acetic acid 1c (0.326 g).

Synthesis of Intermediate 1d

[0049] To a solution of 2-((3-(4-(tert-butoxy)-4-oxobutoxy)-5-methoxyphenyl)amino)-2-(4-fluorophenyl)acetic acid 1c (0.326 g, 0.75 mmol) in DMF (6 mL) were added HATU (0.286 g, 0.75 mmol), triethylamine (0.418 mL, 3.01 mmol) and 6-(trifluoromethyl)indoline [CAS 181513-29-1] (0.141 g, 0.75 mmol). The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with EtOAc and washed with 1N HCl. The organic phase was washed with an aqueous saturated NaHCO.sub.3 solution and brine, dried over MgSO.sub.4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel using a gradient of EtOAc (5% to 50%) in heptane to give tert-butyl 4-(3-((1-(4-fluorophenyl)-2-oxo-2-(6-(trifluoromethyl)indolin-1-yl)ethyl) amino)-5-methoxyphenoxy)butanoate 1d (0.134 g).

Synthesis of Compound 1 and Chiral Separation into Enantiomers 1A and 1B

[0050] To a solution of tert-butyl 4-(3-((1-(4-fluorophenyl)-2-oxo-2-(6-(trifluoromethyl)-indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoate 1d (0.134 g, 0.22 mmol) in CH.sub.2Cl.sub.2 (3 mL) was added a 4M hydrogen chloride solution in dioxane (3 mL, 12 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated under reduced pressure. The residue was triturated with a mixture of Et.sub.2O/heptane. The solids were filtered off and dried under vacuum to give 4-(3-((1-(4-fluorophenyl)-2-oxo-2-(6-(trifluoromethyl)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy) butanoic acid (Compound 1, 103 mg) as a racemic mixture.

[0051] The enantiomers of Compound 1 (1.3 g) were separated via Preparative SFC (Stationary phase: Chiralcel Diacel OD 20250 mm, Mobile phase: CO.sub.2, Ethanol). The product fractions were combined and evaporated under reduced pressure. The first eluted enantiomer was further purified by flash chromatography (Stationary phase: Grace Reveleris silica 40 g, Mobile phase: heptane/EtOAc/EtOH/HOAc gradient 100/0/0/0 to 0/75/24.5/0.5). The desired fractions were combined, evaporated under reduced pressure, and co-evaporated with EtOAc, and then with MeOH/H.sub.2O. The residue was stirred up in H.sub.2O (15 mL)+MeOH (1.5 mL) for 45 minutes, filtered off, washed (4) with MeOH/H.sub.2O (4/1), and dried under vacuum at 45 C. to provide Enantiomer 1A (475 mg). The second eluted enantiomer was further purified by flash chromatography (Stationary phase: Grace Reveleris silica 40 g, Mobile phase: heptane/EtOAc/EtOH/HOAc gradient 100/0/0/0 to 0/75/24.5/0.5). The desired fractions were combined, evaporated under reduced pressure, and co-evaporated with EtOAc, and then with MeOH/H.sub.2O. The residue was stirred up in H.sub.2O (15 mL)+MeOH (1.5 mL) for 75 minutes, filtered off, washed (4) with MeOH/H.sub.2O (4/1), and dried under vacuum at 45 C. to provide Enantiomer 1B (461 mg).

Compound 1

[0052] .sup.1H NMR (300 MHz, DMSO-d.sub.6) ppm 1.80-1.94 (m, 2H) 2.22-2.48 (m, 2H) 3.09-3.27 (m, 2H) 3.62 (s, 3H) 3.85 (t, J=6.2 Hz, 2H) 3.91-4.06 (m, 1H) 4.48-4.61 (m, 1H) 5.57 (d, J=8.7 Hz, 1H) 5.76 (s, 1H) 5.94 (s, 1H) 5.96 (s, 1H) 6.39 (d, J=8.3 Hz, 1H) 7.21 (t, J=8.7 Hz, 2H) 7.35-7.49 (m, 2H) 7.58 (dd, J=8.1, 5.8 Hz, 2H) 8.38 (s, 1H) 12.1 (br. s., 1H) LC/MS (method LC-C): R.sub.t 1.94 min, MH.sup.+ 547

Enantiomer 1A

[0053] .sup.1H NMR (400 MHz, DMSO-d.sub.6) ppm 1.87 (quin, J=6.8 Hz, 2H) 2.33 (t, J=7.4 Hz, 2H) 3.14-3.29 (m, 2H) 3.62 (s, 3H) 3.85 (t, J=6.5 Hz, 2H) 4.00 (td, J=10.5, 7.3 Hz, 1H) 4.54 (td, J=10.4, 6.3 Hz, 1H) 5.56 (d, J=8.6 Hz, 1H) 5.76 (t, J=2.0 Hz, 1H) 5.95 (dt, J=9.1, 1.8 Hz, 2H) 6.36 (d, J=8.8 Hz, 1H) 7.20 (t, J=8.9 Hz, 2H) 7.34-7.41 (m, 1H) 7.42-7.49 (m, 1H) 7.52-7.62 (m, 2H) 8.38 (br s, 1H) 12.10 (br s, 1H)

[0054] LC/MS (method LC-D): R.sub.t 0.99 min, MH.sup.+ 547

[0055] [].sub.D.sup.20: 49.0 (c 0.41, DMF)

[0056] Chiral SFC (method SFC-J): R.sub.t 2.92 min, MH.sup.+ 547 chiral purity 100%.

Enantiomer 1B

[0057] .sup.1H NMR (400 MHz, DMSO-d.sub.6) ppm 1.87 (quin, J=6.9 Hz, 2H) 2.33 (t, J=7.3 Hz, 2H) 3.12-3.29 (m, 2H) 3.62 (s, 3H) 3.85 (t, J=6.5 Hz, 2H) 4.00 (td, J=10.4, 7.2 Hz, 1H) 4.54 (td, J=10.4, 6.3 Hz, 1H) 5.56 (d, J=8.8 Hz, 1H) 5.76 (t, J=2.1 Hz, 1H) 5.95 (dt, J=9.1, 2.0 Hz, 2H) 6.36 (d, J=8.8 Hz, 1H) 7.20 (t, J=8.2 Hz, 2H) 7.35-7.41 (m, 1H) 7.42-7.48 (m, 1H) 7.53-7.62 (m, 2H) 8.38 (br s, 1H) 12.11 (br s, 1H)

[0058] LC/MS (method LC-D): R.sub.t 1.00 min, MH.sup.+ 547

[0059] [].sub.D.sup.20: +49.5 (c 0.525, DMF)

[0060] Chiral SFC (method SFC-J): R.sub.t 2.81 min, MH.sup.+ 547, chiral purity 100%.

Example 2: Synthesis of 4-(3-((1-(4-fluorophenyl)-2-oxo-2-(6-(trifluoromethoxy)-indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic Acid (Compound 2) and Chiral Separation into Enantiomers 2A and 2B

[0061] ##STR00010##

Synthesis of Intermediate 2a

[0062] A mixture of 6-(trifluoromethoxy)indoline [CAS 959235-95-1] (2 g, 9.84 mmol), 2-(4-fluorophenyl)acetic acid [CAS 405-50-5] (1.67 g, 10.8 mmol), HATU (5.6 g, 14.8 mmol) and diisopropylethylamine (4.9 mL, 29.5 mmol) in DMF (40 mL) was stirred at room temperature for 12 h. Water was added and the precipitate was filtered off. The residue was taken up with EtOAc. The organic solution was washed with a 10% aqueous solution of K.sub.2CO.sub.3, brine, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc gradient 90/10 to 60/40). The pure fractions were combined and the solvent was concentrated under reduced pressure to give 2-(4-fluorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone 2a (2.5 g).

Synthesis of intermediate 2b

[0063] At 78 C., under a N.sub.2 flow, LiHMDS 1.5 M in THF (9.82 mL, 14.7 mmol) was added dropwise to a mixture of 2-(4-fluorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)-ethanone 2a (2.5 g, 7.37 mmol) in THF (40 mL). The mixture was stirred for 15 min at 78 C. and a solution of N-bromosuccinimide (1.44 g, 8.1 mmol) in THF (30 mL) was added dropwise. After stirring for 2 h at 78 C., the reaction was quenched with a saturated aqueous solution of NH.sub.4Cl. The mixture was extracted with EtOAc. The organic layer was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure to give, after precipitation from CH.sub.3CN/di isopropyl ether, 2-bromo-2-(4-fluorophenyl)-1-(6-(trifluoromethoxy)-indolin-1-yl)ethanone 2b (3 g). The compound was used as such in the next step.

Synthesis of Intermediate 2c

[0064] A mixture of 2-bromo-2-(4-fluorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)-ethanone 2b (1.1 g, 2.63 mmol), tert-butyl 4-(3-amino-5-methoxyphenoxy)-butanoate 1a (0.74 g, 2.63 mmol) and diisopropylethylamine (0.54 mL, 3.15 mmol) in CH.sub.3CN (40 mL) was stirred at 70 C. for 4 h. The mixture was concentrated under reduced pressure. The residue was diluted with EtOAc, washed with 1N HCl and water. The organic phase was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc 80/20). The pure fractions were combined and evaporated to dryness. The residue was crystallized from diisopropyl ether/petroleum ether, to give tert-butyl 4-(3-((1-(4-fluorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1-yl)ethyl)amino)-5-methoxy-phenoxy)butanoate 2c (1.25 g).

Synthesis of Compound 2 and Chiral Separation into Enantiomers 2A and 2B

[0065] A solution of tert-butyl 4-(3-((1-(4-fluorophenyl)-2-oxo-2-(6-(trifluoromethoxy)-indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoate 2c (1.5 g, 2.42 mmol) in 4M HCl in dioxane (15 mL) and stirred at 5 C. for 3 h and at room temperature for 3 h. The precipitate was filtered off and dried to afford 4-(3-((1-(4-fluorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid as an HCl salt (Compound 2, 1.4 g, 0.76 equiv. HCl, 0.1 equiv. H.sub.2O). Compound 2 (HCl salt) was neutralized prior to chiral separation by treatment of a solution of Compound 2 (HCl salt) in EtOAc or CH.sub.2Cl.sub.2 with 1N NaOH and evaporation of organic layer under reduced pressure. The enantiomers of Compound 2 (1.3 g) were separated via Preparative Chiral SFC (Stationary phase: Chiralcel OD-H 5 m 25030 mm, Mobile phase: 50% CO.sub.2, 50% MeOH) and further purified via reverse phase chromatography (Stationary phase: YMC-actus Triart-C18 10 m 15030 mm, Mobile phase: gradient from 60% HCOONH.sub.4 0.6 g/L pH=3.5, 40% CH.sub.3CN to 0% HCOONH.sub.4 0.6 g/L pH=3.5, 100% CH.sub.3CN). The product fractions were combined and evaporated under reduced pressure. The first eluted enantiomer (205 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 2A (168 mg). The second eluted enantiomer (259 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 2B (180 mg).

Compound 2

[0066] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.9 Hz, 2H) 2.34 (t, J=7.3 Hz, 2H) 3.05-3.28 (m, 2H) 3.62 (s, 3H) 3.85 (t, J=6.5 Hz, 2H) 4.01 (td, J=10.3, 7.4 Hz, 1H) 4.53 (td, J=10.2, 6.6 Hz, 1H) 5.56 (s, 1H) 5.76 (s, 1H) 5.96 (br d, J=10.4 Hz, 2H) 7.01 (br d, J=7.9 Hz, 1H) 7.21 (t, J=8.8 Hz, 2H) 7.33 (d, J=8.2 Hz, 1H) 7.57 (dd, J=8.5, 5.7 Hz, 2H) 8.04 (s, 1H)

[0067] LC/MS (method LC-A): Rt 2.80 min, MH.sup.+ 563

[0068] Melting point: 136 C.

Enantiomer 2A

[0069] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.86 (quin, J=6.9 Hz, 2H) 2.33 (t, J=7.3 Hz, 2H) 3.05-3.26 (m, 2H) 3.61 (s, 3H) 3.84 (t, J=6.3 Hz, 2H) 3.96-4.08 (m, 1H) 4.46-4.60 (m, 1H) 5.55 (d, J=8.8 Hz, 1H) 5.75 (s, 1H) 5.95 (br d, J=11.0 Hz, 2H) 6.41 (br d, J=8.5 Hz, 1H) 7.01 (br d, J=8.2 Hz, 1H) 7.21 (t, J=8.8 Hz, 2H) 7.33 (d, J=8.2 Hz, 1H) 7.57 (dd, J=8.2, 5.7 Hz, 2H) 8.04 (s, 1H) 12.19 (br s, 1H) LC/MS (method LC-A): R.sub.t 2.87 min, MH.sup.+ 563 [].sub.D.sup.20: 46.3 (c 0.27, DMF)

[0070] Chiral SFC (method SFC-B): R.sub.t 1.75 min, MH.sup.+ 563, chiral purity 100%.

Enantiomer 2B

[0071] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.86 (quin, J=6.9 Hz, 2H) 2.32 (t, J=7.3 Hz, 2H) 3.05-3.26 (m, 2H) 3.61 (s, 3H) 3.84 (t, J=6.5 Hz, 2H) 4.01 (td, J=10.3, 7.4 Hz, 1H) 4.53 (td, J=10.2, 6.0 Hz, 1H) 5.55 (d, J=8.8 Hz, 1H) 5.75 (s, 1H) 5.95 (br d, J=12.0 Hz, 2H) 6.41 (d, J=8.8 Hz, 1H) 7.01 (br d, J=7.9 Hz, 1H) 7.20 (t, J=8.7 Hz, 2H) 7.33 (d, J=8.2 Hz, 1H) 7.57 (dd, J=8.5, 5.7 Hz, 2H) 8.04 (s, 1H) 11.49-12.49 (m, 1H)

[0072] LC/MS (method LC-A): R.sub.t 2.87 min, MH.sup.+ 563

[0073] [].sub.D.sup.20: +47.0.sup. (c 0.27, DMF)

[0074] Chiral SFC (method SFC-B): R.sub.t 3.83 min, MH.sup.+ 563, chiral purity 100%.

Example 3: Synthesis of 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethyl)-indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic Acid (Compound 3) and Chiral Separation into Enantiomers 3A and 3B

[0075] ##STR00011##

Synthesis of Intermediate 3a

[0076] A mixture of 6-(trifluoromethyl)indoline [CAS 181513-29-1] (3 g, 16.0 mmol), 2-(4-chlorophenyl)acetic acid [CAS 1878-66-6] (3.53 g, 20.8 mmol), HATU (9.1 g, 24.0 mmol) and diisopropylethylamine (7.95 mL, 48.1 mmol) in DMF (75 mL) was stirred at room temperature for 12 h. Water was added and the precipitate was filtered off. The residue was taken up with EtOAc. The organic solution was washed with a 10% aqueous solution of K.sub.2CO.sub.3, brine, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc gradient 90/10 to 60/40). The pure fractions were combined and the solvent was concentrated under reduced pressure to give 2-(4-chlorophenyl)-1-(6-(trifluoromethyl)indolin-1-yl)-ethanone 3a (4.5 g).

Synthesis of Intermediate 3b

[0077] At 78 C., under a N.sub.2 flow, LiHMDS 1.5 M in THF (17.7 mL, 26.5 mmol) was added dropwise to a mixture of 2-(4-chlorophenyl)-1-(6-(trifluoromethyl)indolin-1-yl)-ethanone 3a (4.5 g, 13.3 mmol) in THF (65 mL). The mixture was stirred for 15 min at 78 C. and a solution of N-bromosuccinimide (2.6 g, 14.6 mmol) in THF (35 mL) was added dropwise. After stirring for 2 h at 78 C., the reaction was quenched with a saturated solution of NH.sub.4Cl. The mixture was extracted with EtOAc. The organic layer was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was taken up with diisopropyl ether. The precipitate was filtered off and discarded (residual succinimide). The filtrate was concentrated under reduced pressure to give 2-bromo-2-(4-chlorophenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone 3b (5 g). The compound was used as such in the next step.

Synthesis of Intermediate 3c

[0078] A mixture of 2-bromo-2-(4-chlorophenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone 3b (5 g, 11.9 mmol), tert-butyl 4-(3-amino-5-methoxyphenoxy)butanoate 1a (3.3 g, 11.9 mmol) and diisopropylethylamine (2.47 mL, 14.3 mmol) in CH.sub.3CN (120 mL) was stirred at 70 C. for 6 h. The mixture was concentrated under reduced pressure, diluted with EtOAc, and washed with 1N HCl and water. The organic phase was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc gradient 90/10 to 60/40). The pure fractions were combined and evaporated to dryness to give tert-butyl 4-(3-((1-(4-chloro-phenyl)-2-oxo-2-(6-(trifluoromethyl)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)-butanoate 3c (1.6 g).

Synthesis of Compound 3 and Chiral Separation into Enantiomers 3A and 3B

[0079] A solution of tert-butyl 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethyl)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoate 3c (1.6 g, 2.58 mmol) in 4M HCl in dioxane (22 mL) was stirred at 5 C. for 3 h and at room temperature for 8 h. The solution was concentrated under reduced pressure. The residue was taken up in CH.sub.3CN/diisopropyl ether. The precipitate was filtered off and dried to afford 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethyl)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid as an HCl salt (1.15 g, 0.95 equiv. HCl, 0.07 equiv. H.sub.2O). A minor part of the Compound 3 (HCl salt) was neutralized by treatment of a solution of Compound 3 (HCl salt) in EtOAc or CH.sub.2Cl.sub.2 with 1N NaOH and evaporation of organic layer under reduced pressure to give Compound 3. The remaining amount of Compound 3 (HCl salt) was used for the chiral separation: the enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralcel OD-H 5 m 25030 mm, Mobile phase: 50% CO.sub.2, 50% iPrOH). The first eluted enantiomer (470 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 3A (404 mg). The second eluted enantiomer (480 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 3B (433 mg).

Compound 3

[0080] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.8 Hz, 2H) 2.33 (t, J=7.3 Hz, 2H) 3.18-3.27 (m, 2H) 3.62 (s, 3H) 3.85 (t, J=6.3 Hz, 2H) 3.97-4.09 (m, 1H) 4.46-4.59 (m, 1H) 5.57 (d, J=8.6 Hz, 1H) 5.76 (s, 1H) 5.95 (br d, J=9.1 Hz, 2H) 6.40 (br d, J=8.6 Hz, 1H) 7.34-7.49 (m, 4H) 7.55 (d, J=8.6 Hz, 2H) 8.38 (s, 1H) 11.90-12.25 (m, 1H)

[0081] LC/MS (method LC-A): Rt 2.88 min, MH.sup.+ 563

[0082] Melting point: 192 C.

Enantiomer 3A

[0083] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (br t, J=6.6 Hz, 2H) 2.34 (br t, J=7.1 Hz, 2H) 3.15-3.31 (m, 2H) 3.62 (s, 3H) 3.85 (br t, J=6.1 Hz, 2H) 3.97-4.09 (m, 1H) 4.48-4.60 (m, 1H) 5.59 (br d, J=8.5 Hz, 1H) 5.77 (br s, 1H) 5.95 (br d, J=11.3 Hz, 2H) 6.44 (br d, J=8.5 Hz, 1H) 7.36-7.50 (m, 4H) 7.56 (br d, J=8.2 Hz, 2H) 8.38 (s, 1H) 12.17 (br s, 1H)

[0084] LC/MS (method LC-A): R.sub.t 2.93 min, MH.sup.+ 563

[0085] [].sub.D.sup.20: 42.4 (c 0.25, DMF)

[0086] Chiral SFC (method SFC-C): R.sub.t 2.12 min, MH.sup.+ 563, chiral purity 100%.

Enantiomer 3B

[0087] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.7 Hz, 2H) 2.34 (br t, J=7.1 Hz, 2H) 3.15-3.31 (m, 2H) 3.62 (s, 3H) 3.85 (br t, J=6.3 Hz, 2H) 3.97-4.10 (m, 1H) 4.49-4.61 (m, 1H) 5.59 (br d, J=8.8 Hz, 1H) 5.77 (s, 1H) 5.95 (br d, J=11.3 Hz, 2H) 6.44 (br d, J=8.5 Hz, 1H) 7.36-7.49 (m, 4H) 7.56 (br d, J=8.2 Hz, 2H) 8.38 (s, 1H) 12.17 (br s, 1H

[0088] LC/MS (method LC-A): R.sub.t 2.93 min, MH.sup.+ 563

[0089] [].sub.D.sup.20: +50.7 (c 0.27, DMF) Chiral SFC (method SFC-C): R.sub.t 4.87 min, MH.sup.+ 563, chiral purity 100%.

Example 4: Synthesis of 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)-indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic Acid (Compound 4) and Chiral Separation into Enantiomers 4A and 4B

[0090] ##STR00012##

Synthesis of Intermediate 4a

[0091] A mixture of 6-(trifluoromethoxy)indoline [CAS 959235-95-1] (2 g, 9.84 mmol), 2-(4-chlorophenyl)acetic acid [CAS 1878-66-6] (1.85 g, 10.8 mmol), HATU (5.6 g, 14.8 mmol) and diisopropylethylamine (4.9 mL, 29.5 mmol) in DMF (40 mL) was stirred at room temperature for 12 h. Water was added and the precipitate was filtered off. The residue was taken up with EtOAc. The organic solution was 1.0 washed with a 10% aqueous solution of K.sub.2CO.sub.3, brine, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc gradient 90/10 to 60/40). The pure fractions were combined and the solvent was concentrated under reduced pressure to give 2-(4-chlorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)-ethanone 4a (3 g).

Synthesis of Intermediate 4b

[0092] At 78 C., under N.sub.2 flow, LiHMDS 1.5 M in THF (11.2 mL, 16.9 mmol) was added dropwise to a mixture of 2-(4-chlorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)-ethanone 4a (3 g, 8.43 mmol) in THF (50 mL). The mixture was stirred for 15 min at 78 C. and a solution of N-bromosuccinimide (1.65 g, 9.3 mmol) in THF (30 mL) was added dropwise. After stirring for 2 h at 78 C., the reaction was quenched with a saturated solution of NH.sub.4Cl. The mixture was extracted with EtOAc. The organic layer was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure to give 2-bromo-2-(4-chlorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone 4b (3.6 g). The compound was used as such in the next step.

Synthesis of Intermediate 4c

[0093] A mixture of 2-bromo-2-(4-chlorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)-ethanone 4b (3.6 g, 8.3 mmol), tert-butyl 4-(3-amino-5-methoxyphenoxy)-butanoate 1a (2.3 g, 8.3 mmol) and diisopropylethylamine (1.7 mL, 9.94 mmol) in CH.sub.3CN (80 mL) was stirred at 70 C. for 4 h. The mixture was concentrated under reduced pressure, diluted with EtOAc, and washed with 1N HCl and water. The organic phase was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography on silica gel (15-40 m, 120 g, heptane/EtOAc 80/20). The pure fractions were combined and evaporated to dryness to give, after crystallization from diisopropyl ether, tert-butyl 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoro-methoxy)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoate 4c (2.6 g).

Synthesis of Compound 4 and Chiral Separation into Enantiomers 4A and 4B

[0094] A solution of tert-butyl 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)-indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoate 4c (2.4 g, 3.8 mmol) in 4M HCl in dioxane (24 mL) was stirred at 5 C. for 3 h and at room temperature for 3 h. The precipitate was filtered off and dried to afford 4-(3-((1-(4-chlorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid as an HCl salt (Compound 4, 2 g, 0.8 equiv. HCl, 0.07 equiv. H.sub.2O). Compound 4 (2 g, HCl salt) was neutralized prior to chiral separation by treatment of a solution of Compound 4 (HCl salt) in ethylacetate with 1N NaOH and evaporation of the organic layer under reduced pressure. The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralcel OD-H 5 m 25030 mm, Mobile phase: 50% CO.sub.2, 50% iPrOH (+0.3% iPrNH.sub.2)) and further purified via Preparative achiral SFC (Stationary phase: Cyano 6 m 15021.2 mm, Mobile phase: 80% CO.sub.2, 20% MeOH (+0.3% iPrNH.sub.2)). The product fractions were combined and evaporated under reduced pressure. The two enantiomers were taken up with EtOAc and washed with 1N HCl. The organic layers were separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The first eluted enantiomer was solidified from ether/diisopropyl ether to give Enantiomer 4A (616 mg). The second eluted enantiomer was solidified from ether/diisopropyl ether to give Enantiomer 4B (715 mg).

[0095] It is also possible to separate the enantiomers starting from the HCl salt of the racemate using the same conditions for chiral separation.

Compound 4

[0096] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.9 Hz, 2H) 2.34 (t, J=7.3 Hz, 2H) 3.07-3.28 (m, 2H) 3.62 (s, 3H) 3.85 (t, J=6.5 Hz, 2H) 4.04 (td, J=10.5, 7.1 Hz, 1H) 4.52 (td, J=10.3, 6.5 Hz, 1H) 5.57 (s, 1H) 5.76 (t, J=2.2 Hz, 1H) 5.90-6.00 (m, 2H) 7.01 (dd, J=8.2, 1.6 Hz, 1H) 7.33 (d, J=8.2 Hz, 1H) 7.41-7.48 (m, 2H) 7.55 (d, J=8.5 Hz, 2H) 8.03 (s, 1H) LC/MS (method LC-B): Rt 2.70 min, MH.sup.+ 579

[0097] Melting point: 150 C.

Enantiomer 4A

[0098] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.7 Hz, 2H) 2.34 (br t, J=7.3 Hz, 2H) 3.08-3.27 (m, 2H) 3.62 (s, 3H) 3.85 (br t, J=6.3 Hz, 2H) 3.99-4.11 (m, 1H) 4.47-4.57 (m, 1H) 5.57 (br s, 1H) 5.76 (s, 1H) 5.95 (br d, J=10.1 Hz, 2H) 6.45 (br s, 1H) 7.01 (br d, J=7.6 Hz, 1H) 7.34 (br d, J=7.9 Hz, 1H) 7.44 (br d, J=8.5 Hz, 2H) 7.55 (br d, J=8.2 Hz, 2H) 8.04 (br s, 1H) 12.12 (br s, 1H)

[0099] LC/MS (method LC-A): R.sub.t 2.95 min, MH.sup.+ 579

[0100] [].sub.D.sup.20: 48.5 (c 0.27, DMF)

[0101] Chiral SFC (method SFC-A): R.sub.t 1.13 min, MH.sup.+ 579, chiral purity 100%.

Enantiomer 4B

[0102] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (br t, J=6.8 Hz, 2H) 2.34 (br t, J=7.3 Hz, 2H) 3.09-3.27 (m, 2H) 3.62 (s, 3H) 3.85 (br t, J=6.1 Hz, 2H) 3.99-4.10 (m, 1H) 4.46-4.59 (m, 1H) 5.57 (s, 1H) 5.76 (br s, 1H) 5.95 (br d, J=10.1 Hz, 2H) 6.45 (br s, 1H) 7.01 (br d, J=7.9 Hz, 1H) 7.34 (br d, J=7.9 Hz, 1H) 7.44 (br d, J=8.2 Hz, 2H) 7.55 (br d, J=8.2 Hz, 2H) 8.04 (br s, 1H) 12.12 (br s, 1H)

[0103] LC/MS (method LC-A): R.sub.t 2.94 min, MH.sup.+ 579

[0104] [].sub.D.sup.20: +42.9 (c 0.28, DMF)

[0105] Chiral SFC (method SFC-A): R.sub.t 2.13 min, MH.sup.+ 579, chiral purity 100%.

Example 5: Synthesis of 4-(3-((1-(4-chlorophenyl)-2-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoic acid (Compound 5) and Chiral Separation into Enantiomers 5A and 5B

[0106] ##STR00013## ##STR00014##

Synthesis of Intermediate 5a

[0107] A mixture of 1-methoxy-4-nitro-2-(trifluoromethyl)benzene [CAS 654-76-2] (24.5 g, 110.8 mmol) and 4-chlorophenoxyacetonitrile [CAS 3598-13-8] (20.4 g, 121.9 mmol) in DMF (100 mL) was added dropwise over 30 min to a stirred solution of tBuOK (27.35 g, 243.7 mmol) in DMF (100 mL) at 10 C. After addition, the purple solution was maintained at 10 C. for 1 h. 500 mL of ice-water and 500 mL of 6N HCl were added and the precipitate was filtered off, washed with water and dried under reduced pressure to afford 40.4 g of 2-(5-methoxy-2-nitro-4-(trifluoromethyl)phenyl)acetonitrile 5a (used as such in the next step).

Synthesis of Intermediate 5b

[0108] A solution of 2-(5-methoxy-2-nitro-4-(trifluoromethyl)phenyl)acetonitrile 5a (26 g, 99.9 mmol) in ethanol/water (9/1) (500 mL) and AcOH (5.2 mL) was hydrogenated for 1 h at a pressure of 3.5 Bar with 10% Pd/C (15.3 g) as the catalyst. The reaction mixture was filtered through a pad of Celite and the filter cake was washed with a solvent mixture of CH.sub.2Cl.sub.2 and CH.sub.3OH. The filtrate was concentrated under reduced pressure. The residue was filtered through a glass filter charged with silica 60-200 m using heptane/EtOAc 80/20 as the eluent. The fractions containing the expected compound were combined and the solvent was concentrated under reduced pressure to give 5-methoxy-6-(trifluoromethyl)-1H-indole 5b (15.6 g).

Synthesis of Intermediate 5c

[0109] At 0 C., BH.sub.3Pyridine (23.5 mL, 232.4 mmol) was added dropwise to a solution of 5-methoxy-6-(trifluoromethyl)-1H-indole 5b (10 g, 46.5 mmol) in EtOH (60 mL). 6N HCl (140 mL) was slowly added while maintaining the temperature below 10 C. The mixture was stirred at 0 C. for 2 h. Water (200 mL) was added and the mixture was basified to pH 8-9 with a concentrated aqueous solution of NaOH (the reaction temperature was kept below 20 C.). The precipitate was filtered off, washed with water (twice) and co-evaporated under reduced pressure with toluene to give 5-methoxy-6-(trifluoromethyl)indoline 5c (9 g).

Synthesis of Intermediate 5d

[0110] A mixture of 5-methoxy-6-(trifluoromethyl)indoline 5c (2 g, 9.21 mmol), 2-(4-chloro-phenyl)acetic acid [CAS 1878-66-6] (1.73 g, 10.1 mmol), HATU (5.25 g, 13.8 mmol) and diisopropylethylamine (4.6 mL, 27.6 mmol) in DMF (40 mL) was stirred at room temperature for 12 h. Water was added and the precipitate was filtered off. The residue was taken up with EtOAc. The organic solution was washed with a 10% aqueous solution of K.sub.2CO.sub.3, brine, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc gradient 90/10 to 60/40). The pure fractions were combined and the solvent was concentrated under reduced pressure to give 2-(4-chlorophenyl)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)-ethanone 5d (3 g).

Synthesis of Intermediate 5e

[0111] At 78 C., under N.sub.2 flow, LiHMDS 1 M in THF (17.3 mL, 17.3 mmol) was added dropwise to a mixture of 2-(4-chlorophenyl)-1-(5-methoxy-6-(trifluoromethyl)-indolin-1-yl)ethanone 5d (3.2 g, 8.65 mmol) in THF (45 mL). TMSCI (1.32 mL, 10.4 mmol) was added dropwise. The mixture was stirred for 15 min at 78 C. and a solution of N-bromosuccinimide (1.85 g, 10.4 mmol) in THF (30 mL) was added dropwise. After stirring for 2 h at 78 C., the reaction was quenched with a saturated solution of NH.sub.4Cl. The mixture was extracted with EtOAc. The organic layer was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure to give 2-bromo-2-(4-chlorophenyl)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone 5e (3.1 g). The compound was used as such in the next step.

Synthesis of Intermediate 5f

[0112] A mixture of 2-bromo-2-(4-chlorophenyl)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone 5e (3.5 g, 7.8 mmol), tert-butyl 4-(3-amino-5-methoxyphenoxy)-butanoate 1a (2.2 g, 7.8 mmol) and diisopropylethylamine (1.6 mL, 9.4 mmol) in CH.sub.3CN (80 mL) was stirred at 70 C. for 4 h. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with 1N HCl and water. The organic phase was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc 80/20). The pure fractions were combined and evaporated to dryness to give, after crystallization from diisopropyl ether, tert-butyl 4-(3-((1-(4-chlorophenyl)-2-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoate 5f (2.1 g).

Synthesis of Compound 5 and Chiral Separation into Enantiomers 5A and 5B

[0113] A solution of tert-butyl 4-(3-((1-(4-chlorophenyl)-2-(5-methoxy-6-(trifluoromethyl)-indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoate 5f (3.1 g, 4.77 mmol) in 4M HCl in dioxane (42.2 mL) was stirred at 5 C. for 3 h and at room temperature for 8 h. The precipitate was filtered off and dried to afford 4-(3-((1-(4-chloro-phenyl)-2-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)-2-oxoethyl)amino)-5-methoxy-phenoxy)butanoic acid as an HCl salt (Compound 5, 2 g). The Enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralpak IA 5 m 25020 mm, Mobile phase: 50% CO.sub.2, 50% iPrOH (+0.3% iPrNH.sub.2+10% CH.sub.2Cl.sub.2)). The product fractions were combined and evaporated under reduced pressure. The two enantiomers were taken up with EtOAc and washed with 1N HCl. The organic layers were separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The first eluted enantiomer (847 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 5A (772 mg). The second eluted enantiomer (840 mg) was solidified from ether/diisopropyl ether to give Enantiomer 5B (724 mg).

Compound 5

[0114] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.9 Hz, 2H) 2.34 (t, J=7.3 Hz, 2H) 3.14-3.35 (m, 2H) 3.61 (s, 3H) 3.80-3.89 (m, 5H) 3.94-4.04 (m, 1H) 4.51 (td, J=10.2, 6.3 Hz, 1H) 5.55 (s, 1H) 5.76 (s, 1H) 5.95 (br d, J=11.7 Hz, 2H) 7.23 (s, 1H) 7.43 (d, J=8.2 Hz, 2H) 7.55 (d, J=8.2 Hz, 2H) 8.34 (s, 1H) LC/MS (method LC-A): Rt 2.86 min, MH.sup.+ 593 Melting point: 130 C.

Enantiomer 5A

[0115] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.9 Hz, 2H) 2.34 (t, J=7.3 Hz, 2H) 3.12-3.31 (m, 2H) 3.62 (s, 3H) 3.81-3.89 (m, 5H) 3.94-4.05 (m, 1H) 4.45-4.56 (m, 1H) 5.55 (br s, 1H) 5.76 (s, 1H) 5.95 (br d, J=11.0 Hz, 2H) 6.40 (br s, 1H) 7.23 (s, 1H) 7.44 (d, J=8.2 Hz, 2H) 7.56 (d, J=8.5 Hz, 2H) 8.34 (s, 1H) 12.14 (br s, 1H)

[0116] LC/MS (method LC-A): R.sub.t 2.85 min, MH.sup.+ 593

[0117] [].sub.D.sup.20: 43.2 (c 0.25, DMF)

[0118] Chiral SFC (method SFC-D): R.sub.t 2.16 min, MH.sup.+ 593, chiral purity 100%.

Enantiomer 5B

[0119] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.8 Hz, 2H) 2.34 (t, J=7.3 Hz, 2H) 3.13-3.33 (m, 2H) 3.62 (s, 3H) 3.79-3.88 (m, 5H) 3.94-4.03 (m, 1H) 4.51 (td, J=10.3, 6.1 Hz, 1H) 5.54 (br s, 1H) 5.75 (s, 1H) 5.95 (br d, J=11.3 Hz, 2H) 6.40 (br s, 1H) 7.23 (s, 1H) 7.43 (d, J=8.2 Hz, 2H) 7.55 (d, J=8.5 Hz, 2H) 8.34 (s, 1H) 12.14 (br s, 1H)

[0120] LC/MS (method LC-A): R.sub.t 2.85 min, MH.sup.+ 593

[0121] [].sub.D.sup.20: +41.4 (c 0.28, DMF)

[0122] Chiral SFC (method SFC-D): R.sub.t 3.75 min, MH.sup.+ 593, chiral purity 99.37%.

Example 6: Synthesis of 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoro-methyl)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic Acid (Compound 6) and Chiral Separation into Enantiomers 6A and 6B

[0123] ##STR00015##

Synthesis of Intermediate 6a

[0124] A mixture of 6-(trifluoromethyl)indoline [CAS 181513-29-1] (2 g, 10.7 mmol), 2-(4-chloro-2-methoxyphenyl)acetic acid [CAS 170737-95-8] (2.36 g, 11.8 mmol), HATU (6.1 g, 16 mmol) and diisopropylethylamine (5.3 mL, 32 mmol) in DMF (50 mL) was stirred at room temperature for 12 h. Water was added and the precipitate was filtered off. The residue was taken up with EtOAc. The organic solution was washed with a 10% aqueous solution of K.sub.2CO.sub.3, brine, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc gradient 90/10 to 60/40). The pure fractions were combined and the solvent was concentrated under reduced pressure to give 2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone 6a (3.9 g).

Synthesis of Intermediate 6b

[0125] At 78 C., under a N.sub.2 flow, LiHMDS 1M in THF (13.5 mL, 13.5 mmol) was added dropwise to a mixture of 2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethyl)-indolin-1-yl)ethanone 6a (2.5 g, 6.76 mmol) in THF (40 mL). The mixture was stirred for 15 min at 78 C. and a solution of N-bromosuccinimide (1.32 g, 7.44 mmol) in THF (20 mL) was added dropwise. After stirring for 2 h at 78 C., the reaction was quenched with a saturated solution of NH.sub.4Cl. The mixture was extracted with EtOAc. The organic layer was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure to give 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone 6b (3 g). The compound was used as such in the next step.

Synthesis of Intermediate 6c

[0126] A mixture of 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone 6b (3 g, 6.69 mmol), tert-butyl 4-(3-amino-5-methoxyphenoxy)-butanoate 1a (1.88 g, 6.69 mmol) and diisopropylethylamine (1.4 mL, 8 mmol) in CH.sub.3CN (100 mL) was stirred at 70 C. for 6 h. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with 1N HCl, and water. The organic phase was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc 80/20). The pure fractions were combined and evaporated to dryness to give tert-butyl 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoromethyl)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoate 6c (1.6 g).

Synthesis of Compound 6 and Chiral Separation into Enantiomers 6A and 6B

[0127] A solution of tert-butyl 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoro-methyl)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoate 6c (1.53 g, 2.36 mmol) in 4M HCl in dioxane (20 mL) was stirred at 5 C. for 3 h and at room temperature for 8 h. The solution was concentrated under reduced pressure. The residue was taken up in CH.sub.3CN/diisopropyl ether. The precipitate was filtered off and dried to afford 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoro-methyl)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid (Compound 6) as an HCl salt (1.35 g, 0.67 equiv. HCl, 0.28 equiv. H.sub.2O). The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralcel OD-H 5 m 2503 0 mm, Mobile phase: 65% CO.sub.2, 35% EtOH). The product fractions were combined and evaporated under reduced pressure. The first eluted enantiomer was further purified via reverse phase chromatography (Stationary phase: YMC-actus Triart-C18 10 m 15030 mm, Mobile phase: gradient from 55% formic acid 0.1%, 45% CH.sub.3CN to 0% formic acid 0.1%, 100% CH.sub.3CN. The pure fractions were combined and evaporated under reduced pressure. The residue (417 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 6A (370 mg). The second eluted enantiomer was further purified via reverse phase chromatography (Stationary phase: YMC-actus Triart-C18 10 m 15030 mm, Mobile phase: gradient from 55% formic acid 0.1%, 45% CH.sub.3CN to 0% formic acid 0.1%, 100% CH.sub.3CN. The pure fractions were combined and evaporated under reduced pressure. The residue (400 mg) then solidified from petroleum ether/diisopropyl ether to give Enantiomer 6B (363 mg).

Compound 6

[0128] .sup.1H NMR (400 MHz, DMSO-d6) ppm 1.87 (br t, J=6.6 Hz, 2H) 2.33 (br t, J=7.3 Hz, 2H) 3.18-3.32 (m, 2H) 3.61 (s, 3H) 3.80-3.87 (m, 2H) 3.90 (s, 3H) 3.96-4.07 (m, 1H) 4.31-4.45 (m, 1H) 5.61 (s, 1H) 5.76 (s, 1H) 5.87 (br d, J=7.6 Hz, 2H) 7.02 (br d, J=8.1 Hz, 1H) 7.14 (s, 1H) 7.32 (d, J=8.1 Hz, 1H) 7.35-7.41 (m, 1H) 7.43-7.50 (m, 1H) 8.37 (s, 1H) LC/MS (method LC-A): Rt 2.90 min, MH.sup.+ 593 Melting point: 130 C.

Enantiomer 6A

[0129] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.9 Hz, 2H) 2.33 (t, J=7.3 Hz, 2H) 3.24 (br dd, J=18.6, 11.7 Hz, 2H) 3.61 (s, 3H) 3.80-3.87 (m, 2H) 3.90 (s, 3H) 3.97-4.06 (m, 1H) 4.33-4.43 (m, 1H) 5.61 (d, J=8.8 Hz, 1H) 5.76 (s, 1H) 5.87 (br d, J=10.4 Hz, 2H) 6.43 (d, J=8.5 Hz, 1H) 7.03 (dd, J=8.2, 1.9 Hz, 1H) 7.15 (d, J=1.6 Hz, 1H) 7.32 (d, J=8.2 Hz, 1H) 7.39 (d, J=7.9 Hz, 1H) 7.46 (d, J=7.9 Hz, 1H) 8.37 (s, 1H) 12.16 (br s, 1H)

[0130] LC/MS (method LC-A): R.sub.t 2.99 min, MH.sup.+ 593

[0131] [].sub.D.sup.20: 28.6 (c 0.29, DMF)

[0132] Chiral SFC (method SFC-E): R.sub.t 2.17 min, MH.sup.+ 593, chiral purity 100%.

[0133] Melting point: 178 C.

Enantiomer 6B

[0134] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.9 Hz, 2H) 2.33 (t, J=7.3 Hz, 2H) 3.24 (br dd, J=18.8, 11.5 Hz, 2H) 3.61 (s, 3H) 3.83 (q, J=6.2 Hz, 2H) 3.90 (s, 3H) 3.96-4.08 (m, 1H) 4.32-4.43 (m, 1H) 5.61 (d, J=8.5 Hz, 1H) 5.76 (s, 1H) 5.87 (br d, J=10.1 Hz, 2H) 6.43 (br d, J=8.5 Hz, 1H) 7.03 (dd, J=8.2, 1.6 Hz, 1H) 7.15 (d, J=1.6 Hz, 1H) 7.32 (d, J=8.2 Hz, 1H) 7.39 (d, J=7.6 Hz, 1H) 7.46 (d, J=7.9 Hz, 1H) 8.37 (s, 1H) 12.16 (br s, 1H)

[0135] LC/MS (method LC-A): R.sub.t 3.00 min, MH.sup.+ 593

[0136] [].sub.D.sup.20: +32.1 (c 0.28, DMF)

[0137] Chiral SFC (method SFC-E): R.sub.t 4.04 min, MH.sup.+ 593, chiral purity 100%.

Example 7: Synthesis of 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoic Acid (Compound 7) and Chiral Separation into Enantiomers 7A and 7B

[0138] ##STR00016##

Synthesis of Intermediate 7a

[0139] A mixture of 5-methoxy-6-(trifluoromethyl)indoline 5c (1.5 g, 6.9 mmol), 2-(4-chloro-2-methoxyphenyl)acetic acid [CAS 170737-95-8] (1.4 g, 6.9 mmol), HATU (3.94 g, 10.4 mmol) and diisopropylethylamine (3.4 mL, 20.7 mmol) in DMF (40 mL) was stirred at room temperature for 12 h. Ice/water was added and the precipitate was filtered off. The residue was taken up with CH.sub.2Cl.sub.2. The organic solution was washed with a 10% aqueous solution of K.sub.2CO.sub.3, brine, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was crystallized from diisopropyl ether to give 2-(4-chloro-2-methoxy-phenyl)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone 7a (2.48 g).

Synthesis of Intermediate 7b

[0140] At 78 C., under a N.sub.2 flow, LiHMDS 1M in THF (16.5 mL, 16.5 mmol) was added dropwise to a mixture of 2-(4-chloro-2-methoxyphenyl)-1-(5-methoxy-6-(trifluoro-methyl)indolin-1-yl)ethanone 7a (3.3 g, 8.25 mmol) in THF (45 mL). TMSCI (1.26 mL, 9.91 mmol) was added dropwise. The mixture was stirred for 15 min at 78 C. and a solution of N-bromosuccinimide (1.76 g, 9.91 mmol) in THF (30 mL) was added dropwise. After stirring for 2 h at 78 C., the reaction was quenched with a saturated solution of NH.sub.4Cl. The mixture was extracted with EtOAc. The organic layer was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure to give 2-bromo-2-(4-chloro-2-methoxy-phenyl)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone 7b (3.5 g). The compound was used as such in the next step.

Synthesis of Intermediate 7c

[0141] A mixture of 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(5-methoxy-6-(trifluoro-methyl)indolin-1-yl)ethanone 7b (3.5 g, 7.31 mmol), tert-butyl 4-(3-amino-5-methoxyphenoxy)butanoate 1a (2 g, 7.31 mmol) and diisopropylethylamine (1.5 mL, 8.8 mmol) in CH.sub.3CN (80 mL) was stirred at 70 C. for 4 h. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with 1N HCl, and water. The organic phase was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc 80/20). The pure fractions were combined and evaporated to dryness to give tert-butyl 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoate 7c (2.2 g).

Synthesis of Compound 7 and Chiral Separation into Enantiomers 7A and 7B

[0142] A solution of tert-butyl 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoate 7c (2.1 g, 3.1 mmol) in 4M HCl in dioxane (27.4 mL) was stirred at 5 C. for 3 h and at room temperature for 8 h. The solution was concentrated under reduced pressure. The residue was taken up in CH.sub.3CN/diisopropyl ether. The precipitate was filtered off and dried to afford 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoic acid (Compound 7) as an HCl salt (1.5 g, 0.74 equiv. HCl, 0.29 equiv. H.sub.2O). The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralcel OD-H 5 m 25030 mm, Mobile phase: 55% CO.sub.2, 45% iPrOH). The product fractions were combined and evaporated under reduced pressure. The first eluted enantiomer (671 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 7A (606 mg). The second eluted enantiomer (647 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 6B (580 mg).

Compound 7

[0143] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.7 Hz, 2H) 2.34 (t, J=7.3 Hz, 2H) 3.17-3.30 (m, 2H) 3.61 (s, 3H) 3.79-3.87 (m, 5H) 3.90 (s, 3H) 3.93-4.02 (m, 1H) 4.29-4.40 (m, 1H) 5.59 (s, 1H) 5.75 (s, 1H) 5.87 (br d, J=10.7 Hz, 2H) 7.02 (dd, J=8.2, 1.6 Hz, 1H) 7.14 (d, J=1.3 Hz, 1H) 7.24 (s, 1H) 7.32 (d, J=8.5 Hz, 1H) 8.32 (s, 1H)

[0144] LC/MS (method LC-A): Rt 2.89 min, MH.sup.+ 623

[0145] Melting point: 160 C.

Enantiomer 7A

[0146] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (br t, J=6.8 Hz, 2H) 2.34 (br t, J=7.1 Hz, 2H) 3.18-3.28 (m, 2H) 3.61 (s, 3H) 3.79-3.87 (m, 5H) 3.91 (s, 3H) 3.94-4.05 (m, 1H) 4.31-4.42 (m, 1H) 5.59 (br d, J=8.2 Hz, 1H) 5.76 (br s, 1H) 5.87 (br d, J=10.4 Hz, 2H) 6.40 (br d, J=8.5 Hz, 1H) 7.02 (br d, J=7.9 Hz, 1H) 7.14 (s, 1H) 7.24 (s, 1H) 7.33 (br d, J=8.2 Hz, 1H) 8.33 (s, 1H) 12.18 (br s, 1H)

[0147] LC/MS (method LC-A): R 2.87 min, MH.sup.+ 623

[0148] [].sub.D.sup.20: 23.9 (c 0.28, DMF)

[0149] Chiral SFC (method SFC-C): R 1.76 min, MH.sup.+ 623, chiral purity 100%.

Enantiomer 7B

[0150] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.5 Hz, 2H) 2.34 (br t, J=7.1 Hz, 2H) 3.18-3.28 (m, 2H) 3.61 (s, 3H) 3.80-3.87 (m, 5H) 3.91 (s, 3H) 3.94-4.02 (m, 1H) 4.28-4.41 (m, 1H) 5.59 (br d, J=8.2 Hz, 1H) 5.75 (br s, 1H) 5.87 (br d, J=10.4 Hz, 2H) 6.40 (br d, J=8.5 Hz, 1H) 7.02 (br d, J=7.9 Hz, 1H) 7.14 (s, 1H) 7.24 (s, 1H) 7.33 (br d, J=8.2 Hz, 1H) 8.33 (s, 1H) 12.17 (br s, 1H)

[0151] LC/MS (method LC-A): R 2.87 min, MH.sup.+ 623

[0152] [].sub.D.sup.20: +28.5 (c 0.26, DMF)

[0153] Chiral SFC (method SFC-C): R 3.52 min, MH.sup.+ 623, chiral purity 100%.

Example 8: Synthesis of 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoro-methoxy)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic Acid (Compound 8) and Chiral Separation into Enantiomers 8A and 8B

[0154] ##STR00017##

Synthesis of Intermediate 8a

[0155] A mixture of 6-(trifluoromethoxy)indoline [CAS 959235-95-1] (2.5 g, 12.3 mmol), 2-(4-chloro-2-methoxyphenyl)acetic acid [CAS 170737-95-8] (2.47 g, 12.3 mmol), HATU (7 g, 18.5 mmol) and diisopropylethylamine (6.1 mL, 36.9 mmol) in DMF (40-mL) was stirred at room temperature for 4 h. Water and EtOAc were added. The organic layer was separated, washed with water, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc 85/15). The pure fractions were combined and the solvent was concentrated under reduced pressure to give, after crystallization from CH.sub.3CN/heptane, 2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone 8a (4.3 g).

Synthesis of Intermediate 8b

[0156] At 78 C., under a N.sub.2 flow, LiHMDS 1M in THF (19.7 mL, 19.7 mmol) was added dropwise to a mixture of 2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethoxy)-indolin-1-yl)ethanone 8a (3.8 g, 9.8 mmol) in THF (50 mL). TMSCI (1.5 mL, 11.8 mmol) was added dropwise. The mixture was stirred for 15 min at 78 C. and a solution of N-bromosuccinimide (1.9 g, 10.8 mmol) in THF (35 mL) was added dropwise. After stirring for 2 h at 78 C., the reaction was quenched with a saturated solution of NH.sub.4Cl. The mixture was extracted with EtOAc. The organic layer was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure to give 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone 8b (4.5 g). The compound was used as such in the next step.

Synthesis of Intermediate 8c

[0157] A mixture of 2-bromo-2-(4-chloro-2-methoxyphenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone 8b (4.5 g, 9.68 mmol), tert-butyl 4-(3-amino-5-methoxyphenoxy)-butanoate 1a (2.7 g, 9.68 mmol) and diisopropylethylamine (2 mL, 11.6 mmol) in CH.sub.3CN (100 mL) was stirred at 70 C. for 4 h. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with 1N HCl and water. The organic phase was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 m, 120 g, heptane/EtOAc 80/20). The pure fractions were combined and evaporated to dryness to give, after crystallization from CH.sub.3CN, tert-butyl 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoro-methoxy)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoate 8c (2.3 g).

Synthesis of Compound 8 and Chiral Separation into Enantiomers 8A and 8B

[0158] A solution of tert-butyl 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoro-methoxy)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoate 8c (2.3 g, 3.46 mmol) in 4M HCl in dioxane (30 mL) was stirred at 5 C. for 3 h and at room temperature for 12 h. The precipitate was filtered off, washed with diisopropyl ether and dried to afford 4-(3-((1-(4-chloro-2-methoxyphenyl)-2-oxo-2-(6-(trifluoro-methoxy)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic acid (Compound 8) as an HCl salt (1.79 g, 0.86 equiv. HCl, 0.22 equiv. H.sub.2O). The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralcel OD-H 5 m 25030 mm, Mobile phase: 65% CO.sub.2, 35% iPrOH). The product fractions were combined and evaporated under reduced pressure. The first eluted enantiomer (726 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 8A (612 mg). The second eluted enantiomer (712 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 8B (643 mg).

Compound 8

[0159] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.9 Hz, 2H) 2.34 (br t, J=7.3 Hz, 2H) 3.08-3.26 (m, 2H) 3.61 (s, 3H) 3.83 (q, J=6.5 Hz, 2H) 3.90 (s, 3H) 3.98-4.09 (m, 1H) 4.31-4.42 (m, 1H) 5.60 (s, 1H) 5.76 (s, 1H) 5.87 (br d, J=9.5 Hz, 2H) 6.98-7.05 (m, 2H) 7.14 (d, J=1.9 Hz, 1H) 7.31 (d, J=8.2 Hz, 1H) 7.34 (d, J=8.2 Hz, 1H) 8.02 (s, 1H)

[0160] LC/MS (method LC-A): Rt 3.04 min, MH.sup.+ 609

[0161] Melting point: 139 C.

Enantiomer 8A

[0162] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.9 Hz, 2H) 2.33 (t, J=7.4 Hz, 2H) 3.09-3.25 (m, 2H) 3.61 (s, 3H) 3.78-3.87 (m, 2H) 3.90 (s, 3H) 3.98-4.07 (m, 1H) 4.32-4.42 (m, 1H) 5.59 (d, J=8.5 Hz, 1H) 5.76 (s, 1H) 5.86 (s, 1H) 5.88 (s, 1H) 6.45 (d, J=8.8 Hz, 1H) 6.97-7.06 (m, 2H) 7.14 (d, J=1.3 Hz, 1H) 7.31 (d, J=8.5 Hz, 1H) 7.34 (d, J=8.2 Hz, 1H) 8.02 (s, 1H) 12.14 (br s, 1H)

[0163] LC/MS (method LC-A): R.sub.t 3.03 min, MH.sup.+ 609

[0164] [].sub.D.sup.20: 39.3 (c 0.28, DMF)

[0165] Chiral SFC (method SFC-F): R.sub.t 2.32 min, MH.sup.+ 609, chiral purity 100%.

Enantiomer 8B

[0166] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.8 Hz, 2H) 2.34 (t, J=7.3 Hz, 2H) 3.09-3.25 (m, 2H) 3.61 (s, 3H) 3.79-3.88 (m, 2H) 3.90 (s, 3H) 4.02 (td, J=10.2, 6.9 Hz, 1H) 4.33-4.41 (m, 1H) 5.60 (s, 1H) 5.76 (s, 1H) 5.86 (s, 1H) 5.88 (s, 1H) 6.45 (br s, 1H) 6.99-7.05 (m, 2H) 7.14 (d, J=1.6 Hz, 1H) 7.31 (d, J=8.5 Hz, 1H) 7.34 (d, J=8.2 Hz, 1H) 8.02 (s, 1H) 12.12 (br s, 1H)

[0167] LC/MS (method LC-A): R.sub.t 3.03 min, MH.sup.+ 609

[0168] [].sub.D.sup.2: +34.5 (c 0.29, DMF)

[0169] Chiral SFC (method SFC-F): R.sub.t 3.51 min, MH.sup.+ 609, chiral purity 100%.

Example 9: Synthesis of 4-(3-((1-(4-chloro-2-fluorophenyl)-2-oxo-2-(6-(trifluoro-methyl)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic Acid (Compound 9) and Chiral Separation into Enantiomers 9A and 9B

[0170] ##STR00018##

Synthesis of Intermediate 9a

[0171] A mixture of 2-(4-chloro-2-fluorophenyl)acetic acid [CAS 194240-75-0] (2.52 g, 13.4 mmol), 6-(trifluoromethyl)indoline [CAS 181513-29-1] (2.5 g, 13.4 mmol), hydroxybenzotriazole (2.7 g, 20.04 mmol), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (3.84 g, 20.04 mmol) and trimethylamine (3.71 mL, 26.7 mmol) in CH.sub.2Cl.sub.2 (30 mL) was stirred at room temperature for 12 h. Water was added and the layers were separated. The organic layer was washed with water, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure to give, after crystallization from CH.sub.3CN/diisopropyl ether, 2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone 9a (3.9 g). The compound was used as such in the next step.

Synthesis of Intermediate 9b

[0172] At 78 C., under a N.sub.2 flow, LiHMDS 1M in THF (13.98 mL, 13.98 mmol) was added dropwise to a mixture of 2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone 9a (2.5 g, 6.99 mmol) in THF (20 mL). The mixture was stirred for 15 min at 78 C. and a solution of N-bromosuccinimide (1.37 g, 7.69 mmol) in THF (15 mL) was added dropwise. After stirring for 2 h at 78 C., the reaction was quenched with a saturated solution of NH.sub.4Cl. The mixture was extracted with EtOAc. The organic layer was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure to give 2-bromo-2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethyl)indolin-1-yl)ethanone 9b (2.8 g). The compound was used as such in the next step.

Synthesis of Intermediate 9c

[0173] A mixture of 2-bromo-2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethyl)indolin-1-yl)-ethanone 9b (2.8 g, 6.41 mmol), tert-butyl 4-(3-amino-5-methoxyphenoxy)-butanoate 1a (1.8 g, 6.41 mmol) and diisopropylethylamine (1.33 mL, 7.7 mmol) in CH.sub.3CN (90 mL) was stirred at 70 C. for 4 h. The mixture was concentrated under reduced pressure, diluted with EtOAc, and washed with 1 N HCl, and water. The organic phase was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc 80/20). The pure fractions were combined and evaporated to dryness to give, after crystallization from CH.sub.3CN/diisopropyl ether, tert-butyl 4-(3-((1-(4-chloro-2-fluorophenyl)-2-oxo-2-(6-(trifluoromethyl)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoate 9c (1.75 g).

Synthesis of Compound 9 and Chiral Separation into Enantiomers 9A and 9B

[0174] A solution of tert-butyl 4-(3-((1-(4-chloro-2-fluorophenyl)-2-oxo-2-(6-(trifluoro-methyl)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoate 9c (1.75 g, 2.75 mmol) in 4M HCl in dioxane (24.3 mL) was stirred at 5 C. for 3 h and at room temperature for 8 h. The mixture was concentrated under reduced pressure. The residue was crystallized from CH.sub.3CN/diisopropyl ether to afford 4-(3-((1-(4-chloro-2-fluorophenyl)-2-oxo-2-(6-(trifluoromethyl)indolin-1-yl)ethyl)amino)-5-methoxy-phenoxy)butanoic acid (Compound 9) as an HCl salt (1.4 g, 0.8 equiv. HCl, 0.78 equiv. H.sub.2O). The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralpak AD-H 5 m 25030 mm, Mobile phase: 70% CO.sub.2, 30% iPrOH). The product fractions were combined and evaporated under reduced pressure. The first eluted enantiomer (618 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 9A (505 mg). The second eluted enantiomer (548 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 9B (495 mg).

Compound 9

[0175] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.9 Hz, 2H) 2.34 (t, J=7.3 Hz, 2H) 3.18-3.34 (m, 2H) 3.63 (s, 3H) 3.80-3.90 (m, 2H) 4.02-4.14 (m, 1H) 4.40-4.49 (m, 1H) 5.72 (s, 1H) 5.80 (s, 1H) 5.94 (br d, J=10.1 Hz, 2H) 7.33 (dd, J=8.5, 1.6 Hz, 1H) 7.39-7.43 (m, 1H) 7.43-7.50 (m, 3H) 8.36 (s, 1H)

[0176] LC/MS (method LC-A): Rt 2.99 min, MH.sup.+ 581

[0177] Melting point: 110 C.

Enantiomer 9A

[0178] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.7 Hz, 2H) 2.33 (br t, J=7.1 Hz, 2H) 3.22-3.28 (m, 2H) 3.62 (s, 3H) 3.80-3.90 (m, 2H) 4.03-4.13 (m, 1H) 4.39-4.48 (m, 1H) 5.72 (br d, J=8.8 Hz, 1H) 5.80 (s, 1H) 5.93 (br d, J=10.7 Hz, 2H) 6.60 (br d, J=8.8 Hz, 1H) 7.33 (br d, J=7.9 Hz, 1H) 7.39-7.43 (m, 1H) 7.43-7.51 (m, 3H) 8.36 (s, 1H) 12.19 (br s, 1H)

[0179] LC/MS (method LC-A): R.sub.t 2.98 min, MH.sup.+ 581

[0180] [].sub.D.sup.20: 30.0 (c 0.29, DMF)

[0181] Chiral SFC (method SFC-G): R.sub.t 1.97 min, MH.sup.+ 581, chiral purity 100%.

Enantiomer 9B

[0182] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.9 Hz, 2H) 2.33 (t, J=7.3 Hz, 2H) 3.21-3.28 (m, 2H) 3.63 (s, 3H) 3.80-3.91 (m, 2H) 4.02-4.12 (m, 1H) 4.40-4.49 (m, 1H) 5.72 (d, J=9.1 Hz, 1H) 5.80 (s, 1H) 5.94 (br d, J=11.0 Hz, 2H) 6.60 (br d, J=8.8 Hz, 1H) 7.33 (dd, J=8.2, 1.6 Hz, 1H) 7.38-7.43 (m, 1H) 7.43-7.50 (m, 3H) 8.36 (s, 1H) 11.04-12.93 (m, 1H)

[0183] LC/MS (method LC-A): R.sub.t 2.98 min, MH.sup.+ 581

[0184] [].sub.D.sup.20: +27.9 (c 0.28, DMF)

[0185] Chiral SFC (method SFC-G): R.sub.t 3.19 min, MH.sup.+ 581, chiral purity 99.35%.

Example 10: Synthesis of 4-(3-((1-(4-chloro-2-fluorophenyl)-2-oxo-2-(6-(trifluoro-methoxy)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoic Acid (Compound 10) and Chiral Separation into Enantiomers 10A and 10B

[0186] ##STR00019##

Synthesis of Intermediate 10a

[0187] HATU (7.02 g, 18.46 mmol) was added to a mixture of 6-(trifluoromethoxy)indoline

[0188] [CAS 959235-95-1] (2.5 g, 12.3 mmol), 2-(4-chloro-2-fluorophenyl)acetic acid [CAS 194240-75-0] (2.32 g, 12.3 mmol) and diisopropylethylamine (6.1 mL, 36.9 mmol) in DMF (100 mL). The resulting mixture was stirred at room temperature for 12 h. The mixture was diluted with water, the precipitate was filtered off, and washed with water. The residue was taken up with EtOAc and the organic solution was washed with a 10% aqueous solution of K.sub.2CO.sub.3, brine, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue product was crystallized from diisopropyl ether to give 2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone 10a (4 g).

Synthesis of Intermediate 10b

[0189] At 78 C., under a N.sub.2 flow, LiHMDS 1M in THF (21.4 mL, 21.4 mmol) was added dropwise to a mixture of 2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone 10a (4 g, 10.7 mmol) in THF (60 mL). The mixture was stirred for 15 min at 78 C. and a solution of N-bromosuccinimide (2.1 g, 11.8 mmol) in THF (40 mL) was added dropwise. After stirring for 2 h at 78 C., the reaction was quenched with a saturated solution of NH.sub.4Cl. The mixture was extracted with EtOAc. The organic layer was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure to give 2-bromo-2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone 10b (4.8 g). The compound was used as such in the next step.

Synthesis of Intermediate 10c

[0190] A mixture of 2-bromo-2-(4-chloro-2-fluorophenyl)-1-(6-(trifluoromethoxy)indolin-1-yl)ethanone 10b (3 g, 6.63 mmol), tert-butyl 4-(3-amino-5-methoxyphenoxy)-butanoate 1a (1.86 g, 6.63 mmol) and diisopropylethylamine (1.37 mL, 7.95 mmol) in CH.sub.3CN (60 mL) was stirred at 70 C. for 4 h. The mixture was concentrated under reduced pressure, diluted with EtOAc, and washed with 1N HCl 1N and water. The organic phase was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 m, 120 g, heptane/EtOAc 80/20). The pure fractions were combined and evaporated to dryness to give tert-butyl 4-(3-((1-(4-chloro-2-fluorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1-yl) ethyl)amino)-5-methoxyphenoxy)butanoate 10c (835 mg).

Synthesis of Compound 10 and Chiral Separation into Enantiomers 10A and 10B

[0191] A solution of tert-butyl 4-(3-((1-(4-chloro-2-fluorophenyl)-2-oxo-2-(6-(trifluoro-methoxy)indolin-1-yl)ethyl)amino)-5-methoxyphenoxy)butanoate 10c (835 mg, 1.28 mmol) in 4M HCl in dioxane (11.3 mL) was stirred at 5 C. for 3 h and at room temperature for 8 h. The solution was concentrated under reduced pressure. The residue was solidified from diisopropyl ether to afford 4-(3-((1-(4-chloro-2-fluorophenyl)-2-oxo-2-(6-(trifluoromethoxy)indolin-1-yl)ethyl)amino)-5-methoxy-phenoxy)butanoic acid (Compound 10) (620 mg). The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralpak IC 5 m 25030 mm, Mobile phase: 70% CO.sub.2, 30% iPrOH (+0.3% iPrNH.sub.2). The product fractions were combined and evaporated under reduced pressure. The first eluted enantiomer (249 mg) was taken up with EtOAc and washed with 1N HCl. The organic layer was separated, dried over MgSO.sub.4, filtered and concentrated under reduced pressure. The residue was solidified from petroleum ether/diisopropyl ether to give Enantiomer 10A (183 mg). The second eluted enantiomer (274 mg) was taken up with EtOAc and washed with 1N HCl. The organic layer was separated, dried over MgSO.sub.4, filtered and concentrated under reduced pressure. The residue was solidified from petroleum ether/diisopropyl ether to give Enantiomer 10B (186 mg).

Compound 10

[0192] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.8 Hz, 2H) 2.33 (br t, J=7.3 Hz, 2H) 3.09-3.24 (m, 2H) 3.62 (s, 3H) 3.81-3.89 (m, 2H) 4.05-4.13 (m, 1H) 4.38-4.47 (m, 1H) 5.70 (br d, J=9.1 Hz, 1H) 5.79 (s, 1H) 5.93 (br d, J=9.8 Hz, 2H) 6.62 (br d, J=8.8 Hz, 1H) 7.03 (br d, J=8.2 Hz, 1H) 7.31-7.37 (m, 2H) 7.41-7.50 (m, 2H) 8.02 (s, 1H) 12.15 (br s, 1H)

[0193] LC/MS (method LC-A): Rt 3.07 min, MH.sup.+ 597

Enantiomer 10A

[0194] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.9 Hz, 2H) 2.34 (t, J=7.3 Hz, 2H) 3.12-3.22 (m, 2H) 3.62 (s, 3H) 3.79-3.90 (m, 2H) 4.04-4.13 (m, 1H) 4.38-4.48 (m, 1H) 5.70 (d, J=8.8 Hz, 1H) 5.79 (s, 1H) 5.93 (br d, J=9.8 Hz, 2H) 6.62 (d, J=8.8 Hz, 1H) 7.03 (br d, J=9.5 Hz, 1H) 7.30-7.38 (m, 2H) 7.41-7.51 (m, 2H) 8.02 (s, 1H) 12.10 (br s, 1H)

[0195] LC/MS (method LC-A): R.sub.t 3.04 min, MH.sup.+ 597

[0196] [].sub.D.sup.20: +23.1 (c 0.26, DMF)

[0197] Chiral SFC (method SFC-H): R.sub.t 3.22 min, MH.sup.+ 597, chiral purity 100%.

Enantiomer 10B

[0198] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (br t, J=6.8 Hz, 2H) 2.34 (br t, J=7.3 Hz, 2H) 3.12-3.25 (m, 2H) 3.63 (s, 3H) 3.80-3.90 (m, 2H) 4.05-4.14 (m, 1H) 4.38-4.49 (m, 1H) 5.71 (br d, J=9.1 Hz, 1H) 5.80 (br s, 1H) 5.94 (br d, J=9.5 Hz, 2H) 6.62 (br d, J=8.8 Hz, 1H) 7.03 (br d, J=7.9 Hz, 1H) 7.30-7.38 (m, 2H) 7.41-7.52 (m, 2H) 8.02 (br s, 1H) 12.12 (br s, 1H)

[0199] LC/MS (method LC-A): R.sub.t 3.04 min, MH.sup.+ 597

[0200] [].sub.D.sup.20: 23.0 (c 0.3, DMF)

[0201] Chiral SFC (method SFC-H): R.sub.t 4.05 min, MH.sup.+ 597, chiral purity 100%.

Example 11: Synthesis of 4-(3-((1-(4-chloro-2-fluorophenyl)-2-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoic Acid (Compound 11) and Chiral Separation into Enantiomers 11A and 11B

[0202] ##STR00020##

Synthesis of Intermediate 11a

[0203] HATU (5.25 g, 13.81 mmol) was added to a mixture of 5-methoxy-6-(trifluoro-methyl)indoline 5c (2 g, 9.21 mmol), 2-(4-chloro-2-fluorophenyl)acetic acid [CAS 194240-75-0] (1.74 g, 9.21 mmol) and diisopropylethylamine (4.57 mL, 27.6 mmol) in DMF (50 mL). The resulting mixture was stirred at room temperature for 12 h. The mixture was diluted with ice/water. The precipitate was filtered off and washed with water. The residue was taken up with CH.sub.2Cl.sub.2 and the organic solution was washed with a 10% aqueous solution of K.sub.2CO.sub.3, brine, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was crystallized from diisopropyl ether to give 2-(4-chloro-2-fluorophenyl)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone 11a (3.4 g).

Synthesis of Intermediate 11 b

[0204] At 78C, under a N.sub.2 flow, LiHMDS 1M in THF (17.5 mL, 17.5 mmol) was added dropwise to a mixture of 2-(4-chloro-2-fluorophenyl)-1-(5-methoxy-6-(trifluoro-methyl)indolin-1-yl)ethanone 11a (3.4 g, 8.77 mmol) in THF (45 mL). TMSCI (1.34 mL, 10.5 mmol) was added dropwise. The mixture was stirred for 15 min at 78 C. and a solution of N-bromosuccinimide (1.87 g, 10.52 mmol) in THF (30 mL) was added dropwise. After stirring for 2 h at 78 C., the reaction was quenched with a saturated solution of NH.sub.4Cl. The mixture was extracted with EtOAc. The organic layer was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure to give 2-bromo-2-(4-chloro-2-fluorophenyl)-1-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)ethanone 11 b (4 g). The compound was used as such in the next step.

Synthesis of Intermediate 11c

[0205] A mixture of 2-bromo-2-(4-chloro-2-fluorophenyl)-1-(5-methoxy-6-(trifluoromethyl)-indolin-1-yl)ethanone 11b (4 g, 8.57 mmol), tert-butyl 4-(3-amino-5-methoxy-phenoxy)butanoate 1a (2.4 g, 8.57 mmol) and diisopropylethylamine (1.77 mL, 10.3 mmol) in CH.sub.3CN (100 mL) was stirred at 70 C. for 4 h. The mixture was concentrated under reduced pressure, diluted with EtOAc and washed with 1N HCl and water. The organic phase was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The compound was purified by flash chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc 80/20). The compound was further purified via achiral SFC (stationary phase: 2-ethylpyridine 5 m 15030 mm, mobile phase: 85% CO.sub.2, 15% MeOH). The pure fractions were combined and evaporated to dryness to give tert-butyl 4-(3-((1-(4-chloro-2-fluorophenyl)-2-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoate 11c (2.6 g).

Synthesis of Compound 11 and Chiral Separation into Enantiomers 11A and 11B

[0206] A solution of tert-butyl 4-(3-((1-(4-chloro-2-fluorophenyl)-2-(5-methoxy-6-(trifluoro-methyl)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoate 11c (2.2 g, 3.3 mmol) in 4M HCl in dioxane (29.2 mL) was stirred at 5 C. for 3 h and at room temperature for 8 h. The solution was concentrated under reduced pressure. The residue was crystallized from CH.sub.3CN/diisopropyl ether to afford 4-(3-((1-(4-chloro-2-fluorophenyl)-2-(5-methoxy-6-(trifluoromethyl)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoic acid (Compound 11) as an HCl salt (800 mg, 0.85 equiv. HCl, 0.36 equiv. H.sub.2O). This fraction was combined with another batch (total amount: 1.8 g) for chiral separation. The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralcel OD-H 5 m 25030 mm, Mobile phase: 55% CO.sub.2, 45% iPrOH). The product fractions were combined and evaporated under reduced pressure. The first eluted enantiomer (788 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 11A (693 mg). The second eluted enantiomer (771 mg) was solidified from petroleum ether/diisopropyl ether to give Enantiomer 11B (695 mg).

Compound 11

[0207] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.87 (quin, J=6.8 Hz, 2H) 2.34 (br t, J=7.4 Hz, 2H) 3.18-3.31 (m, 2H) 3.63 (s, 3H) 3.85 (s, 5H) 3.98-4.09 (m, 1H) 4.37-4.48 (m, 1H) 5.69 (s, 1H) 5.79 (s, 1H) 5.93 (br d, J=11.0 Hz, 2H) 7.26 (s, 1H) 7.32 (br d, J=8.5 Hz, 1H) 7.44-7.52 (m, 2H) 8.32 (s, 1H)

[0208] LC/MS (method LC-A): Rt 2.90 min, MH.sup.+ 611

[0209] Melting point: 121 C.

Enantiomer 11A

[0210] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.88 (quin, J=6.8 Hz, 2H) 2.34 (t, J=7.3 Hz, 2H) 3.18-3.29 (m, 2H) 3.63 (s, 3H) 3.86 (s, 5H) 3.99-4.07 (m, 1H) 4.38-4.47 (m, 1H) 5.69 (br s, 1H) 5.79 (s, 1H) 5.93 (br d, J=10.7 Hz, 2H) 6.55 (br s, 1H) 7.25 (s, 1H) 7.32 (dd, J=8.5, 1.3 Hz, 1H) 7.43-7.51 (m, 2H) 8.33 (s, 1H) 12.13 (br s, 1H)

[0211] LC/MS (method LC-A): R.sub.t 2.90 min, MH.sup.+ 611

[0212] [].sub.D.sup.20: 23.9 (c 0.26, DMF)

[0213] Chiral SFC (method SFC-C): R.sub.t 1.70 min, MH.sup.+ 611, chiral purity 100%.

Enantiomer 11B

[0214] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.88 (quin, J=6.8 Hz, 2H) 2.34 (br t, J=7.3 Hz, 2H) 3.18-3.31 (m, 2H) 3.63 (s, 3H) 3.85 (s, 5H) 3.99-4.07 (m, 1H) 4.37-4.47 (m, 1H) 5.69 (br s, 1H) 5.79 (s, 1H) 5.93 (br d, J=11.0 Hz, 2H) 6.56 (br s, 1H) 7.25 (s, 1H) 7.32 (br d, J=8.2 Hz, 1H) 7.43-7.50 (m, 2H) 8.33 (s, 1H) 12.13 (br s, 1H)

[0215] LC/MS (method LC-A): R.sub.t 2.89 min, MH.sup.+ 611

[0216] [].sub.D.sup.20: +24.0 (c 0.25, DMF)

[0217] Chiral SFC (method SFC-C): R.sub.t 2.96 min, MH.sup.+ 611, chiral purity 100%.

Example 12: Synthesis of 4-(3-((1-(4-chlorophenyl)-2-(5-methoxy-6-(trifluoro-methoxy)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoic Acid (Compound 12) and Chiral Separation into Enantiomers 12A and 12B

[0218] ##STR00021## ##STR00022##

Synthesis of Intermediate 12a

[0219] A solution of 4-methoxy-3-(trifluoromethoxy)aniline [CAS 647855-21-8] (3.1 g, 15.0 mmol) in toluene (50 mL) was treated with N-bromosuccinimide (2.8 g, 15.7 mmol) at 5 C. and the resulting mixture was stirred at 5-10 C. for 2 h. The mixture was quenched with water and extracted with EtOAc. The combined extracts were dried over MgSO.sub.4, filtered and evaporated under reduced pressure. Purification was done by flash chromatography on silica gel (15-40 m, 24 g, heptane/EtOAc gradient 95/5 to 90/10) The pure fractions were combined and evaporated to dryness to give 2-bromo-4-methoxy-5-(trifluoromethoxy)aniline 12a (2.5 g).

Synthesis of Intermediate 12b

[0220] A solution of 2-bromo-4-methoxy-5-(trifluoromethoxy)aniline 12a (2.72 g, 9.51 mmol) in DMF (30 mL) was degassed with N.sub.2 for 15 min. Dichlorobis-(triphenylphosphine)palladium (667 mg, 0.95 mmol), copper(I) iodide (362 mg, 1.90 mmol), triethylamine (3.96 mL, 28.5 mmol) and trimethylsilylacetylene (3.95 mL, 28.53 mmol) were added. The reaction mixture was heated at 70 C. for 12 h under N.sub.2 flow. After cooling to room temperature, the reaction mixture was diluted with H.sub.2O and extracted with EtOAc. The organic phases were combined, dried over MgSO.sub.4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc 85/15). The pure fractions were combined and evaporated to dryness to give 4-methoxy-5-(trifluoromethoxy)-2-((trimethylsilyl)ethynyl)aniline 12b (1.4 g).

Synthesis of Intermediate 12c

[0221] To a solution of 4-methoxy-5-(trifluoromethoxy)-2-((trimethylsilyl)ethynyl)aniline 12b (1.2 g, 3.96 mmol) in NMP (11 mL) under N.sub.2 flow was added tBuOK (1.33 g, 11.9 mmol) in one portion. The reaction mixture was heated at 80 C. for 4 h; after cooling to room temperature, the mixture was poured into ice/water and acidified with 3N HCl until pH 4-5. The reaction mixture was extracted with EtOAc. The organic phases were combined, washed with H.sub.2O, dried over MgSO.sub.4, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 m, 40 g, heptane/EtOAc 85/15). The pure fractions were combined and evaporated to dryness to give 5-methoxy-6-(trifluoromethoxy)-1H-indole 12c (490 mg).

Synthesis of Intermediate 12d

[0222] At 0 C., BH.sub.3Pyridine (10.5 mL, 103.8 mmol) was added dropwise to a solution of 5-methoxy-6-(trifluoromethoxy)-1H-indole 12c (8 g, 34.6 mmol) in EtOH (45 mL). 6N HCl (6 mL) was slowly added while maintaining the temperature below 10 C. The mixture was stirred at 0 C. for 3 h. Water (210 mL) was added and the mixture was basified until pH 8-9 with a concentrated solution of NaOH in water (during the addition, the reaction temperature was kept below 20 C.). The mixture was extracted with EtOAc. The organic layer was washed with water, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. Toluene was added and the solution was concentrated under reduced pressure to give 7.5 g of 5-methoxy-6-(trifluoromethoxy)indoline 12d.

Synthesis of Intermediate 12e

[0223] A mixture of 5-methoxy-6-(trifluoromethoxy)indoline 12d (1 g, 4.29 mmol), 2-(4-chlorophenyl)acetic acid [CAS 1878-66-6] (805 mg, 4.72 mmol), HATU (2.44 g, 6.43 mmol) and diisopropylethylamine (2.13 mL, 12.87 mmol) in DMF (20 mL) was stirred at room temperature for 12 h. Ice/water was added and the precipitate was filtered off. The residue was taken up with CH.sub.2Cl.sub.2. The organic solution was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure to give 2-(4-chlorophenyl)-1-(5-methoxy-6-(trifluoromethoxy)indolin-1-yl)ethanone 12e (1.68 g).

Synthesis of Intermediate 12f

[0224] At 78 C., under a N.sub.2 flow, LiHMDS 1M in THF (8.3 mL, 8.3 mmol) was added dropwise to a mixture of 2-(4-chlorophenyl)-1-(5-methoxy-6-(trifluoromethoxy)-indolin-1-yl)ethanone 12e (1.6 g, 4.15 mmol) in THF (25 mL). TMSCI (0.63 mL, 4.98 mmol) was added dropwise. The mixture was stirred for 15 min at 78 C. and a solution of N-bromosuccinimide (0.89 g, 4.98 mmol) in THF (15 mL) was added dropwise. After stirring for 2 h at 78 C., the reaction was quenched with a saturated solution of NH.sub.4Cl. The mixture was extracted with EtOAc. The organic layer was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure to give 2-bromo-2-(4-chlorophenyl)-1-(5-methoxy-6-(trifluoromethoxy)indolin-1-yl)ethanone 12f (2.3 g, purity (by LC): 50%). The compound was used as such in the next step.

Synthesis of Intermediate 12 g

[0225] A mixture of 2-bromo-2-(4-chlorophenyl)-1-(5-methoxy-6-(trifluoromethoxy)indolin-1-yl)ethanone 12f (2.3 g, 2.48 mmol, purity (by LC): 50%), tert-butyl 4-(3-amino-5-methoxyphenoxy)butanoate 1a (0.696 g, 2.48 mmol) and diisopropylethylamine (0.512 mL, 2.97 mmol) in CH.sub.3CN (25 mL) was stirred at 70 C. for 4 h. The mixture was concentrated under reduced pressure, diluted with EtOAc, and washed with 1N HCl, and water. The organic phase was separated, dried over MgSO.sub.4, filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography on silica gel (15-40 m, 80 g, heptane/EtOAc 80/20). The fractions containing product were combined and evaporated under reduced pressure and the residue was purified again by flash chromatography on silica gel (15-40 m, 40 g, CH.sub.2Cl.sub.2). The pure fractions were combined and evaporated to dryness to give tert-butyl 4-(3-((1-(4-chlorophenyl)-2-(5-methoxy-6-(trifluoro-methoxy)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoate 12 g (920 mg).

Synthesis of Compound 12 and Chiral Separation into Enantiomers 12A and 12B

[0226] A solution of tert-butyl 4-(3-((1-(4-chlorophenyl)-2-(5-methoxy-6-(trifluoromethoxy)-indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoate 12 g (920 mg, 1.38 mmol) in 4M HCl in dioxane (15 mL) was stirred at 5 C. for 3 h and at room temperature for 12 h. The precipitate was filtered off, washed with diisopropyl ether and dried to afford 4-(3-((1-(4-chlorophenyl)-2-(5-methoxy-6-(trifluoro-methoxy)indolin-1-yl)-2-oxoethyl)amino)-5-methoxyphenoxy)butanoic acid (Compound 12, 802 mg, 0.2 equiv. H.sub.2O). The enantiomers were separated via Preparative Chiral SFC (Stationary phase: Chiralpak AD-H 5 m 25020 mm, Mobile phase: 50% CO.sub.2, 50% iPrOH). The product fractions were combined and evaporated under reduced pressure. The first eluted enantiomer (260 mg) was solidified from heptane/diisopropyl ether to give Enantiomer 12A (165 mg). The second eluted enantiomer (241 mg) was solidified from heptane/diisopropyl ether to give Enantiomer 12B (184 mg).

Compound 12

[0227] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.86 (quin, J=6.9 Hz, 2H) 2.33 (t, J=7.3 Hz, 2H) 3.08-3.28 (m, 2H) 3.61 (s, 3H) 3.81 (s, 3H) 3.84 (br t, J=6.5 Hz, 2H) 3.97-4.06 (m, 1H) 4.48 (td, J=10.4, 6.3 Hz, 1H) 5.53 (s, 1H) 5.75 (s, 1H) 5.94 (br d, J=10.1 Hz, 2H) 7.20 (s, 1H) 7.43 (d, J=8.5 Hz, 2H) 7.54 (d, J=8.5 Hz, 2H) 8.06 (s, 1H)

[0228] LC/MS (method LC-A): Rt 2.89 min, MH.sup.+ 609

Enantiomer 12A

[0229] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.86 (quin, J=6.8 Hz, 2H) 2.33 (t, J=7.3 Hz, 2H) 3.09-3.26 (m, 2H) 3.61 (s, 3H) 3.81 (s, 3H) 3.84 (br t, J=6.5 Hz, 2H) 4.02 (td, J=10.3, 7.1 Hz, 1H) 4.48 (td, J=10.4, 6.3 Hz, 1H) 5.53 (d, J=8.5 Hz, 1H) 5.75 (s, 1H) 5.93 (s, 1H) 5.95 (s, 1H) 6.43 (d, J=8.8 Hz, 1H) 7.20 (s, 1H) 7.43 (d, J=8.2 Hz, 2H) 7.55 (d, J=8.5 Hz, 2H) 8.06 (s, 1H) 12.12 (br s, 1H)

[0230] LC/MS (method LC-A): R.sub.t 2.92 min, MH.sup.+ 609

[0231] [].sub.D.sup.20: 44.2 (c 0.197, DMF)

[0232] Chiral SFC (method SFC-I): R.sub.t 0.99 min, MH.sup.+ 609, chiral purity 100%.

Enantiomer 12B

[0233] .sup.1H NMR (500 MHz, DMSO-d6) ppm 1.86 (quin, J=6.9 Hz, 2H) 2.33 (t, J=7.3 Hz, 2H) 3.09-3.27 (m, 2H) 3.61 (s, 3H) 3.81 (s, 3H) 3.84 (br t, J=6.5 Hz, 2H) 3.98-4.06 (m, 1H) 4.48 (td, J=10.5, 6.1 Hz, 1H) 5.53 (d, J=8.8 Hz, 1H) 5.75 (s, 1H) 5.93 (s, 1H) 5.95 (s, 1H) 6.43 (d, J=8.8 Hz, 1H) 7.20 (s, 1H) 7.43 (d, J=8.5 Hz, 2H) 7.54 (d, J=8.5 Hz, 2H) 8.06 (s, 1H) 12.16 (br s, 1H)

[0234] LC/MS (method LC-A): R.sub.t 2.91 min, MH.sup.+ 609

[0235] [].sub.D.sup.20: +40.7 (c 0.189, DMF)

[0236] Chiral SFC (method SFC-I): R.sub.t 1.45 min, MH.sup.+ 609, chiral purity 98.53%.

TABLE-US-00003 TABLE compounds prepared as described above Compound Structure Optical rotation 1 [00023] racemic 1A [00024] [].sub.D.sup.20 = 49.0 1B [00025] [].sub.D.sup.20 = +49.5 2 [00026] racemic 2A [00027] [].sub.D.sup.20 = 46.3 2B [00028] [].sub.D.sup.20 = +47.0 3 [00029] racemic 3A [00030] [].sub.D.sup.20 = 42.4 3B [00031] [].sub.D.sup.20 = +50.7 4 [00032] racemic 4A [00033] [].sub.D.sup.20 = 48.5 4B [00034] [].sub.D.sup.20 = +42.9 5 [00035] racemic 5A [00036] [].sub.D.sup.20 = 43.2 5B [00037] [].sub.D.sup.20 = +41.4 6 [00038] racemic 6A [00039] [].sub.D.sup.20 = 28.6 6B [00040] [].sub.D.sup.20 = +32.1 7 [00041] racemic 7A [00042] [].sub.D.sup.20 = 23.9 7B [00043] [].sub.D.sup.20 = +28.5 8 [00044] racemic 8A [00045] [].sub.D.sup.20 = 39.3 8B [00046] [].sub.D.sup.20 = +34.5 9 [00047] racemic 9A [00048] [].sub.D.sup.20 = 30.0 9B [00049] [].sub.D.sup.20 = +27.9 10 [00050] racemic 10A [00051] [].sub.D.sup.20 = +23.1 10B [00052] [].sub.D.sup.20 = 23.0 11 [00053] racemic 11A [00054] [].sub.D.sup.20 = 23.9 11B [00055] [].sub.D.sup.20 = +24.0 12 [00056] racemic 12A [00057] [].sub.D.sup.20 = 44.2 12B [00058] [].sub.D.sup.20 = +40.7

Antiviral Activity of the Compounds of the Invention

DENV-2 Antiviral Assay

[0237] The antiviral activity of all the compounds of the invention was tested against the DENV-2 16681 strain which was labeled with enhanced green fluorescent protein (eGPF). The culture medium consists of minimal essential medium supplemented with 2% of heat-inactivated fetal calf serum, 0.04% gentamycin (50 mg/mL) and 2 mM of L-glutamine. Vero cells, obtained from ECACC, were suspended in culture medium and 25 L was added to 384-well plates (2500 cells/well), which already contain the antiviral compounds. Typically, these plates contain a 5-fold serial dilution of 9 dilution steps of the test compound at 200 times the final concentration in 100% DMSO (200 nL). In addition, each compound concentration is tested in quadruplicate (final concentration range: 25 M-0.000064 M or 2.5 M -0.0000064 M for the most active compounds). Finally, each plate contains wells which are assigned as virus controls (containing cells and virus in the absence of compound), cell controls (containing cells in the absence of virus and compound) and medium controls (containing medium in the absence of cells, virus and compounds). To the wells assigned as medium control, 25 L of culture medium was added instead of Vero cells. Once the cells were added to the plates, the plates were incubated for 30 minutes at room temperature to allow the cells to distribute evenly within the wells. Next, the plates were incubated in a fully humidified incubator (37 C., 5% CO.sub.2) until the next day. Then, DENV-2 strain 16681, labeled with eGFP, was added at a multiplicity of infection (MOI) of 0.5. Therefore, 15 L of virus suspension was added to all the wells containing test compound and to the wells assigned as virus control. In parallel, 15 L of culture medium was added to the medium and cell controls. Next, the plates were incubated for 3 days in a fully humidified incubator (37 C., 5% CO.sub.2). At the day of the read out, the eGFP fluorescence was measured using an automated fluorescence microscope at 488 nm (blue laser). Using an in-house LIMS system, inhibition dose response curves for each compound were calculated and the half maximal effective concentration (EC.sub.50) was determined. Therefore, the percent inhibition (I) for every test concentration is calculated using the following formula: I=100*(S.sub.TS.sub.CC)/(S.sub.VCS.sub.CC); S.sub.T, S.sub.CC and S.sub.VC are the amount of eGFP signal in the test compound, cell control and virus control wells, respectively. The EC.sub.50 represents the concentration of a compound at which the virus replication is inhibited with 50%, as measured by a 50% reduction of the eGFP fluorescent intensity compared to the virus control. The EC.sub.50 is calculated using linear interpolation (Table 1).

[0238] In parallel, the toxicity of the compounds was assessed on the same plates. Once the read-out for the eGFP signal was done, 40 L of ATPlite, a cell viability stain, was added to all wells of the 384-well plates. ATP is present in all metabolically active cells and the concentration declines very rapidly when the cells undergo necrosis or apoptosis. The ATPLite assay system is based on the production of light caused by the reaction of ATP with added luciferase and D-luciferin. The plates were incubated for 10 minutes at room temperature. Next, the plates were measured on a ViewLux. The half maximal cytotoxic concentration (CO.sub.50) was also determined, defined as the concentration required to reduce the luminescent signal by 50% compared to that of the cell control wells. Finally, the selectivity index (SI) was determined for the compounds, which was calculated as followed: SI=CC.sub.50/EC.sub.50.

TABLE-US-00004 TABLE 1 EC.sub.50, CC.sub.50, and SI for the compounds of the invention in the DENV-2 antiviral assay compound# EC.sub.50 (M) N CC.sub.50 (M) N SI N 1 0.0021 4 >25 4 >12022 4 1A 0.18 3 >25 3 >76 3 1B 0.00084 3 20 3 26500 3 2 0.00055 3 12 4 22200 3 2A 0.056 3 14 3 248 3 2B 0.00024 3 20 3 214720 3 3 0.00048 3 13 5 20300 3 3A 0.0039 6 11 7 3200 6 3B 0.00014 8 13 8 111100 8 4 0.00015 4 10 4 >46100 4 4A 0.031 7 10 8 345 7 4B 0.00012 23 13 23 92400 23 5 0.00062 3 13 3 26000 3 5A 0.019 3 12 3 625 3 5B 0.00018 3 13 3 87500 3 6 0.00031 6 12 7 32100 6 6A 0.023 3 12 3 527 3 6B 0.00013 5 13 5 >209126 5 7 0.00047 3 12 3 24500 3 7A 0.024 3 12 3 508 3 7B 0.00017 3 13 3 101083 3 8 0.00013 3 12 3 112292 3 8A 0.28 4 12 4 43 4 8B 0.000066 6 14 7 >62700 6 9 0.00096 3 11 3 12700 3 9A 0.031 3 12 3 392 3 9B 0.00040 3 13 3 28400 3 10 0.00024 3 10 3 44300 3 10A 0.00019 3 13 3 79200 3 10B 0.0055 3 8.8 3 1620 3 11 0.00066 3 11 3 20600 3 11A 0.015 3 12 3 837 3 11B 0.00015 3 12 3 124345 3 12 0.00073 4 12 4 17700 4 12A 0.38 3 12 3 32 3 12B 0.00035 3 12 3 34900 3 N = the number of independent experiments in which the compounds were tested.

Tetravalent Reverse Transcriptase Quantitative-PCR (RT-qPCR) Assay

[0239] The antiviral activity of the compounds of the invention was tested against DENV-1 strain TC974#666 (NCPV), DENV-2 strain 16681, DENV-3 strain H87 (NCPV) and DENV-4 strain H241 (NCPV) in a RT-qPCR assay. Therefore, Vero cells were infected with either DENV-1, or -2, or -3, or -4 in the presence or absence of test compounds. At day 3 post-infection, the cells were lysed and cell lysates were used to prepare cDNA of both a viral target (the 3UTR of DENV; Table 2) and a cellular reference gene (-actin, Table 2). Subsequently, a duplex real time PCR was performed on a Lightcycler480 instrument. The generated Cp value is inversely proportional to the amount of RNA expression of these targets. Inhibition of DENV replication by a test compound results in a shift of Cp's for the 3UTR gene. On the other hand, if a test compound is toxic to the cells, a similar effect on -actin expression will be observed. The comparative Cp method is used to calculate EC.sub.50, which is based on the relative gene expression of the target gene (3UTR) normalized with the cellular housekeeping gene (-actin). In addition, CC.sub.50 values are determined based on the C.sub.p values acquired for the housekeeping gene -actin.

TABLE-US-00005 TABLE2 Primersandprobesusedforthereal-time, quantitativeRT-PCR. Primer/ probe Target Sequence.sup.a,b F3utr258 DENV3- 5-CGGTTAGAGGAGACCCCTC-3 UTR R3utr425 DENV3- 5-GAGACAGCAGGATCTCTGGTC-3 UTR P3utr343 DENV3- 5-AAGGACTAG-ZEN- UTR AGGTTAGAGGAGACCCCCC-3 Factin743 -actin 5-GGCCAGGTCATCACCATT-3 Ractin876 -actin 5-ATGTCCACGTCACACTTCATG-3 Pactin773 -actin 5-TTCCGCTGC CCTGAGGCT CTC-3- .sup.aReporter dyes (FAM, HEX) and quenchers (ZEN and IABkFQ) elements are indicated in bold and italics. .sup.bThe nucleotide sequence of the primers and probes were selected from the conserved region in the 3UTR region of the dengue virus genome, based on the alignment of 300 nucleotide sequences of the four dengue serotypes deposited in Genbank (Gong et al., 2013, Methods Mol Biol, Chapter 16).

[0240] The culture medium consisted of minimal essential medium supplemented with 2% of heat-inactivated fetal calf serum, 0.04% gentamycin (50 mg/mL) and 2 mM of L-glutamine. Vero cells, obtained from ECACC, were suspended in culture medium and 75 L/well was added in 96-well plates (10000 cells/well), which already contain the antiviral compounds. Typically, these plates contain a 5-fold serial dilution of 9 dilution steps of the test compound at 200 times the final concentration in 100% DMSO (500 nL; final concentration range: 25 M-0.000064 M or 2.5 M-0.0000064 M for the most active compounds). In addition, each plate contains wells which are assigned as virus controls (containing cells and virus in the absence of compound) and cell controls (containing cells in the absence of virus and compound). Once the cells were added in the plates, the plates were incubated in a fully humidified incubator (37 C., 5% CO.sub.2) until the next day. Dengue viruses serotype-1, -2, -3 and -4 were diluted in order to obtain a Cp of 22-24 in the assay. Therefore, 25 L of virus suspension was added to all the wells containing test compound and to the wells assigned as virus control. In parallel, 25 L of culture medium was added to the cell controls. Next, the plates were incubated for 3 days in a fully humidified incubator (37 C., 5% CO.sub.2). After 3 days, the supernatant was removed from the wells and the cells were washed twice with ice-cold PBS (100 L). The cell pellets within the 96-well plates were stored at 80 C. for at least 1 day. Next, RNA was extracted using the Cells-to-CT lysis kit, according to the manufacturer's guideline (Life Technologies). The cell lysates can be stored at 80 C. or immediately used in the reverse transcription step.

[0241] In preparation of the reverse transcription step, mix A (table 3A) was prepared and 7.57 L/well was dispensed in a 96-well plate. After addition of 5 L of the cell lysates, a five minute denaturation step at 75 C. was performed (table 3B). Afterwards, 7.43 L of mix B was added (table 3C) and the reverse transcription step was initiated (table 3D) to generate cDNA.

[0242] Finally, a RT-qPCR mix was prepared, mix C (table 4A), and 22.02 L/well was dispensed in 96-well LightCycler qPCR plates to which 3 L of cDNA was added and the qPCR was performed according to the conditions in table 4B on a LightCycler 480.

[0243] Using the LightCycler software and an in-house LIMS system, dose response curves for each compound were calculated and the half maximal effective concentration (EC.sub.50) and the half maximal cytotoxic concentration (CC.sub.50) were determined (Tables 5-8).

TABLE-US-00006 TABLE 3 cDNA synthesis using Mix A, denaturation, Mix B and reverse transcription. A Mix A Plates 8 Samples 828 Reaction Vol. (l) 20 Volume for (l) Concentration 1 x Mix Item Unit Stock Final sample samples Milli-Q H.sub.2O 7.27 6019.56 R3utr425 M 20 0.27 0.15 124.20 Ractin876 M 20 0.27 0.15 124.20 Volume mix/well (l) 7.57 Cell lysates 5.00 B Denaturation step: Step Temp Time Denaturation 75 C. 5 Hold 4 C. hold C Mix B Samples 864 Volume for (l) Concentration 1 x Mix Item Unit Stock Final sample samples Expand HIFI buffer 2 X 10.00 1.00 2.00 1728.0 MgCl.sub.2 mM 25.00 3.50 2.80 2419.2 dNTPs mM 10.00 1.00 2.00 1728.0 Rnase inhibitor U/l 40.00 1.00 0.50 432.0 Expand RT U/l 50.00 0.33 0.13 112.3 Total Volume Mi (l) 7.43 D Protocol cDNA synthesis Step Temp Time Rev transc 42 C. 30 Denaturation 99 C. 5 Hold 4 C. hold

TABLE-US-00007 TABLE 4 qPCR mix and protocol. A Mix C Samples 833 Reaction Vol. (l) 25 Volume for (l) Concentration 1 x Mix Item Unit Stock Final sample samples H.sub.2O PCR grade 7.74 6447.42 Roche Roche 2xMM mix X 2 1 12.50 10412.50 F3utr258 M 20 0.3 0.38 316.54 R3utr425 M 20 0.3 0.38 316.54 P3utr343 M 20 0.1 0.13 108.29 Factin743 M 20 0.3 0.38 316.54 Ractin876 M 20 0.3 0.38 316.54 Pactin773 M 20 0.1 0.13 108.29 Volume Mix/Tube (l) 22.02 cDNA 3.00 B Protocol qPCR3 Step Temp Time Ramp rate preincub/denat 95 C. 10 min 4.4 Denaturation 95 C. 10 sec 4.4 40 cycles annealing 58 C. 1 min 2.2 Elongation 72 C. 1 sec 4.4 Cooling 40 C. 10 sec 1.5

TABLE-US-00008 TABLE 5 EC.sub.50, CC.sub.50, and SI for the compounds against serotype 1 in the RT-qPCR assays Protocol A RT-qPCR serotype 1 TC974#666 compound# EC.sub.50 (M) N CC.sub.50 (M) N SI N 1B 0.00028 4 14 4 34200 4 2B 0.00030 4 >2.5 4 >19400 4 3B 0.00018 3 >2.5 3 >30300 3 4B 0.000048 7 >2.5 7 >85800 7 5B 0.00074 4 >2.5 4 >6700 4 6B 0.00047 3 >2.5 3 >8420 3 7B 0.00061 3 >2.5 3 >6020 3 8B 0.00015 4 >2.5 4 >30700 4 9B 0.00022 4 >2.5 4 >24000 4 10A 0.00016 4 >2.5 4 >33300 4 11B 0.00067 4 >2.5 4 >6970 4 12B 0.00068 3 >2.5 3 >6820 3 N = the number of independent experiments in which the compounds were tested.

TABLE-US-00009 TABLE 6 EC.sub.50, CC.sub.50, and SI for the compounds against serotype 2 in the RT-qPCR assays Protocol A RT-qPCR serotype 2 16681 compound# EC.sub.50 (M) N CC.sub.50 (M) N SI N 1B 0.00048 4 18 3 38000 3 2B 0.00028 3 14 3 76100 3 3B 0.00012 3 10 3 81700 3 4B 0.000060 7 >2.5 5 >65500 5 5B 0.00017 3 >2.5 3 >16000 3 6B 0.00015 3 >2.5 3 >23800 3 7B 0.00028 4 >2.5 4 >34500 4 8B 0.000062 3 >2.5 3 >43700 3 9B 0.00030 3 >2.5 3 >18200 3 10A 0.00020 3 >2.5 3 >24400 3 11B 0.00017 3 >2.5 3 >18300 3 12B 0.00022 3 >2.5 3 >12900 3 N = the number of independent experiments in which the compounds were tested.

TABLE-US-00010 TABLE 7 EC.sub.50, CC.sub.50, and SI for the compounds against serotype 3 in the RT-qPCR assays Protocol A RT-qPCR serotype 3 H87 compound# EC.sub.50 (M) N CC.sub.50 (M) N SI N 1B 0.0034 3 >2.5 3 >909 3 2B 0.0046 3 >2.5 3 >1200 3 3B 0.0011 3 >2.5 3 >5170 3 4B 0.00066 7 >2.5 6 >5610 6 5B 0.0046 3 >2.5 3 >1050 3 6B 0.0017 3 >2.5 3 >2170 3 7B 0.0058 3 >2.5 3 >1080 3 8B 0.0010 3 >2.5 3 >2740 3 9B 0.0041 3 >2.5 3 >1360 3 10A 0.0021 3 >2.5 3 >1290 3 11B 0.0054 3 >2.5 3 >604 3 12B 0.0041 3 >2.5 3 >1240 3 N = the number of independent experiments in which the compounds were tested.

TABLE-US-00011 TABLE 8 EC.sub.50, CC.sub.50, and SI for the compounds against serotype 4 in the RT-qPCR assays Protocol A RT-qPCR serotype 4 H241 compound# EC.sub.50 (M) N CC.sub.50 (M) N SI N 1B 0.051 4 8.3 3 173 3 2B 0.030 4 9.5 4 587 4 3B 0.014 3 1.2 3 85 3 4B 0.011 10 9.1 9 682 9 5B 0.024 3 9.6 3 530 3 6B 0.016 3 >2.5 3 >232 3 7B 0.025 3 9.4 3 531 3 8B 0.012 3 5.8 3 334 3 9B 0.031 3 15 3 570 3 10A 0.010 3 15 2 2640 2 11B 0.022 3 11 3 697 3 12B 0.028 3 10 3 348 3 N = the number of independent experiments in which the compounds were tested.

PRIOR ART EXAMPLES

[0244] Compounds (56) and (170) disclosed in WO-2013/045516 have been tested in an analogous DENV-2 antiviral assay as the compounds of the present invention and their reported activity is listed below.

##STR00059##

TABLE-US-00012 TABLE 9 EC.sub.50, CC.sub.50, and SI for compounds (56) and(170) disclosed in the DENV-2 antiviral assay compound# EC.sub.50 (M) CC.sub.50 (M) SI (56) of WO-2013/045516 0.45 >139 >312 (170) of WO-2013/045516 0.44 26 58

Abbreviations Used in Experimental Part

[0245]

TABLE-US-00013 (M + H).sup.+ protonated molecular ion aq. aqueous Boc tert-butyloxycarbonyl Boc.sub.2O di-tert-butyl dicarbonate br broad CH.sub.3CN acetonitrile CHCl.sub.3 chloroform CH.sub.2Cl.sub.2 dichloromethane CO.sub.2 carbon dioxide d doublet DCM dichloromethane DIEA diisopropylethylamine DIPE diisopropyl ether DMA dimethylacetamide DMAP 4-dimethylaminopyridine DME 1,2-dimethoxyethane DMF dimethylformamide DMSO dimethyl sulfoxide eq. equivalent Et.sub.2O diethyl ether Et.sub.3N triethylamine EtOAc ethyl acetate EtOH ethanol H.sub.2O water H.sub.2SO.sub.4 sulfuric acid HCl hydrochloric acid HPLC high performance liquid chromatography iPrNH.sub.2 isopropylamine IprOH 2-propanol K.sub.2CO.sub.3 potassium carbonate K.sub.3PO.sub.4 potassium orthophosphate LiAlH.sub.4 lithium aluminium hydride m/z mass-to-charge ratio Me methyl MeOH methanol MgSO.sub.4 magnesium sulfate min minute(s) N.sub.2 nitrogen Na.sub.2CO.sub.3 sodium carbonate Na.sub.2SO.sub.4 sodium sulfate NaBH.sub.4 sodium borohydride NaHCO.sub.3 sodium bicarbonate NaNO.sub.2 sodium nitrite NaOH sodium hydroxide q quartet rt or RT room temperature s singlet t triplet tBuOH tert-butanol TEA triethylamine TFA trifluoroacetic acid THF tetrahydrofuran TMSCl trimethylsilyl chloride